

Embargoed for release until approved by ASA House of Delegates. No part of this document may be released, distributed or reprinted until approved. Any unauthorized copying, reproduction, appropriation or communication of the contents of this document without the express written consent of the American Society of Anesthesiologists is subject to civil and criminal prosecution to the fullest extent possible, including punitive damages.

**Practice Advisory on Anesthetic Care for Magnetic Resonance Imaging**  
*American Society of Anesthesiologists*

*An Updated Report by the American Society of Anesthesiologists Task Force on Anesthetic Care for Magnetic Resonance Imaging\**

1 PRACTICE advisories are systematically developed reports that are intended to assist  
2 decision-making in areas of patient care. Advisories provide a synthesis and analysis of expert  
3 opinion, clinical feasibility data, open forum commentary, and consensus surveys. Practice  
4 advisories developed by the American Society of Anesthesiologists (ASA) are not intended as  
5 standards, guidelines, or absolute requirements and their use cannot guarantee any specific  
6 outcome. They may be adopted, modified, or rejected according to clinical needs and  
7 constraints, and are not intended to replace local institutional policies.

8 Practice advisories are not supported by scientific literature to the same degree as  
9 standards or guidelines because of the lack of sufficient numbers of adequately controlled  
10 studies. Practice advisories are subject to periodic revision as warranted by the evolution of  
11 medical knowledge, technology, and practice.

12 This document updates the “Practice Advisory on Anesthetic Care for Magnetic Resonance  
13 Imaging, adopted by the ASA in 2008 and published in 2009.”<sup>†</sup>

---

\* Updated by the Committee on Standards and Practice Parameters, Jeffrey L. Apfelbaum, M.D. (Committee Chair), Chicago, Illinois; Mark A. Singleton, M.D. (Task Force Co-Chair), San Jose, California; Jan Ehrenwerth, M.D. (Task Force Co-Chair), Madison, Connecticut; Charlotte Bell, M.D., Milford, Connecticut; Richard T. Connis, Ph.D., Woodinville, Washington; Keira P. Mason, M.D., Wellesley Hills, Massachusetts; Craig D. McClain, M.D., Brookline, Massachusetts; David G. Nickinovich, Ph.D., Bellevue, Washington; Warren S. Sandberg, M.D., Ph.D., Nashville, Tennessee.

Supported by the American Society of Anesthesiologists under the direction of Jeffrey L. Apfelbaum, M.D., Chair, Committee on Standards and Practice Parameters. A complete list of references used to develop this Advisory is available by writing to the American Society of Anesthesiologists.

Address correspondence to the American Society of Anesthesiologists: 520 N. Northwest Highway, Park Ridge, Illinois 60068-2573. This Practice Advisory, as well as all published ASA Practice Parameters, may be obtained at no cost through the Journal Web site, [www.anesthesiology.org](http://www.anesthesiology.org).

<sup>†</sup> American Society of Anesthesiologists: Practice Advisory on Anesthetic Care for Magnetic Resonance Imaging. *ANESTHESIOLOGY* 2009; 110:459-479

14 **Methodology**

15 *A. Definition of anesthetic care for MRI and high-risk imaging*

16 This Advisory defines anesthetic care for MRI as moderate sedation, deep sedation,  
17 monitored anesthesia care, general anesthesia, or ventilatory and critical care support. High-risk  
18 imaging refers to imaging in patients with medical or health-related risks, imaging with  
19 equipment-related risks, and procedure-related risks such as MRI-guided surgery, minimally-  
20 invasive procedures (*e.g.*, focused ultrasound, radiofrequency ablation), or cardiac and airway  
21 imaging studies.

22 *B. Purpose*

23 The magnetic resonance imaging (MRI) suite is a hazardous location because of the  
24 presence of a very strong static magnetic field, high frequency electromagnetic (radiofrequency  
25 [RF]) waves, and a time-varied (pulsed) magnetic field. Secondary dangers of these energy  
26 sources include high-level acoustic noise, systemic and localized heating, and accidental  
27 projectiles. There may be significant challenges to anesthetic administration and monitoring  
28 capabilities due to static and dynamic magnetic fields as well as RF energy emissions. Direct  
29 patient observation may be compromised by noise, darkened environment, obstructed line of  
30 sight, and other characteristics unique to this environment (*e.g.*, distractions). Unlike a  
31 conventional operating room, the MRI environment frequently requires the anesthesiologist to  
32 assume broader responsibility for immediate patient care decisions.

33 The purposes of this updated Advisory are to: (1) promote patient and staff safety in the  
34 MRI environment, (2) prevent the occurrence of MRI-associated accidents, (3) promote optimal  
35 patient management and reduce adverse patient outcomes associated with MRI, (4) identify  
36 potential equipment-related hazards in the MRI environment, (5) identify limitations of  
37 physiologic monitoring capabilities in the MRI environment, and (6) identify potential health  
38 hazards (*e.g.*, high decibel levels) of the MRI environment.

39 *C. Focus*

40 This updated Advisory focuses on MRI settings where anesthetic care is provided, Four  
41 zones within the MRI suite have been identified, with ascending designations indicating  
42 increased hazard areas.<sup>1,2</sup> These areas within the MRI suite are categorized as zones I-  
43 IV (*Appendix 1*).

44 *D. Application*

45 This updated Advisory is intended for use by anesthesiologists or other individuals working  
46 under the supervision of an anesthesiologist, and applies to anesthetic care performed,  
47 supervised or medically directed by anesthesiologists or to moderate sedation care supervised  
48 by other physicians. Because the safe conduct of MRI procedures requires close collaboration  
49 and prompt coordination between anesthesiologists, radiologists, MRI technologists, and nurses,  
50 some responsibilities are shared among the disciplines. When shared responsibilities are  
51 described in this Advisory, the intent is to give the anesthesiologist a starting-point for  
52 participating in the allocation and understanding of shared responsibilities. The Advisory may  
53 also serve as a resource for other physicians and health care professionals (*e.g.*, technologists,  
54 nurses, safety officers, hospital administrators, biomedical engineers, and industry  
55 representatives).

56 This updated Advisory does not address specific anesthetic drug choices, and does not apply  
57 to patients who receive minimal sedation (anxiolysis) in order to complete the scan or procedure  
58 safely and comfortably.

59 *E. Task Force Members and Consultants*

60 In 2013, the ASA Committee on Standards and Practice Parameters requested that scientific  
61 evidence for this Advisory be updated. The update consists of an evaluation of literature that  
62 includes new studies obtained after publication of the original Advisory.

63 The original Advisory was developed by an ASA appointed Task Force of 13 members.

64 These individuals included ten anesthesiologists in private and academic practice from various  
65 geographic areas of the United States, a radiologist, and two consulting methodologists from  
66 the ASA Committee on Standards and Practice Parameters.

67 The Task Force developed the original Advisory by means of a seven-step process. First,  
68 they reached consensus on the criteria for evidence. Second, a systematic review and evaluation  
69 was performed on original published research studies from peer-reviewed journals relevant to  
70 MRI safety. Third, a panel of expert consultants was asked to: (1) participate in opinion surveys  
71 on the effectiveness of various MRI safety strategies (2) review and comment on a draft of the  
72 Advisory developed by the Task Force. Fourth, opinions about the Advisory were solicited  
73 from a random sample of active members of the ASA. Fifth, the Task Force held an open  
74 forum at two major national meetings<sup>‡</sup> to solicit input on its draft recommendations. Sixth, the  
75 consultants were surveyed to assess their opinions on the feasibility of implementing this  
76 Advisory. Seventh, all available information was used to build consensus within the Task Force  
77 to create the final document. A summary of recommendations is found in Appendix 2.

78 *F. Availability and Strength of Evidence*

79 Preparation of this update used the same methodological process as was used in the original  
80 Advisory to obtain new scientific evidence. Opinion-based evidence obtained from the original  
81 Advisory is reported in this update. The protocol for reporting each source of evidence is  
82 described below.

83 **Scientific Evidence:**

84 Scientific evidence used in the development of this updated Advisory is based on  
85 cumulative findings from literature published in peer-reviewed journals. Literature citations are  
86 obtained from PubMed and other healthcare databases, direct internet searches, Task Force

---

<sup>‡</sup> International Anesthesia Research Society, 82<sup>nd</sup> Clinical and Scientific Congress, San Francisco, California, March 30, 2008; Society for Pediatric Anesthesia, Annual Meeting; San Diego, California, April 5, 2008.

87 members, liaisons with other organizations and from manual searches of references located in  
88 reviewed articles.

89 Findings from the aggregated literature are reported in the text of the Advisory by evidence  
90 category, level, and direction. Evidence categories refer specifically to the strength and quality  
91 of the *research design* of the studies. Category A evidence represents results obtained from  
92 randomized controlled trials (RCTs), and Category B evidence represents observational results  
93 obtained from non-randomized study designs or RCTs without pertinent controls. When  
94 available, Category A evidence is given precedence over Category B evidence in the reporting  
95 of results. These evidence categories are further divided into evidence levels. Evidence levels  
96 refer specifically to the strength and quality of the summarized study *findings* (*i.e.*, statistical  
97 findings, type of data, and the number of studies reporting/replicating the findings) within the  
98 two evidence categories. For this document, only the highest level of evidence is included in  
99 the summary report for each intervention, including a directional designation of benefit, harm,  
100 or equivocality for each outcome.

101 *Category A:* RCTs report comparative findings between clinical interventions for specified  
102 outcomes. Statistically significant ( $p < 0.01$ ) outcomes are designated as either beneficial (B)  
103 or harmful (H) for the patient; statistically non-significant findings are designated as equivocal  
104 (E).

105 Level 1: The literature contains a sufficient number of RCTs to conduct meta-analysis,<sup>§</sup> and  
106 meta-analytic findings from these aggregated studies are reported as evidence. No meta-  
107 analyses were conducted for this Advisory.

---

<sup>§</sup> All meta-analyses are conducted by the ASA methodology group. Meta-analyses from other sources are reviewed but not included as evidence in this document.

PRACTICE ADVISORY

108 Level 2: The literature contains multiple RCTs, but the number of RCTs is not sufficient to  
109 conduct a viable meta-analysis for the purpose of this updated Advisory. Findings from these  
110 RCTs are reported as evidence.

111 Level 3: The literature contains a single RCT, and findings from this study are reported as  
112 evidence.

113 *Category B:* Observational studies or RCTs without pertinent comparison groups may  
114 permit *inference* of beneficial or harmful relationships among clinical interventions and  
115 outcomes. Inferred findings are given a directional designation of beneficial (B), harmful (H)  
116 or equivocal (E). For studies that report statistical findings, the threshold for significance is  $p <$   
117 0.01.

118 Level 1: The literature contains observational comparisons (*e.g.*, cohort, case-control  
119 research designs) between clinical interventions for a specified outcome.

120 Level 2: The literature contains observational studies with associative statistics (*e.g.*,  
121 relative risk, correlation, sensitivity/specificity).

122 Level 3: The literature contains non-comparative observational studies with descriptive  
123 statistics (*e.g.*, frequencies, percentages).

124 Level 4: The literature contains case reports.

125 *Insufficient Literature:* The *lack* of sufficient scientific evidence in the literature may occur  
126 when the evidence is either unavailable (*i.e.*, no pertinent studies found) or inadequate.

127 Inadequate literature cannot be used to assess relationships among clinical interventions and  
128 outcomes, since such literature does not permit a clear interpretation of findings due to  
129 methodological concerns (*e.g.*, confounding in study design or implementation) or does not  
130 meet the criteria for content as defined in the “Focus” of the Advisory.

131 **Opinion-Based Evidence:**

132 The original Advisory contained formal survey information collected from expert

133 consultants and a random sample of members of the ASA. Additional information was obtained  
 134 from open forum presentations and other invited and public sources. All opinion-based  
 135 evidence relevant to each topic (*e.g.*, original survey data, original open-forum testimony,  
 136 Internet-based comments, letters, editorials) is considered in the development of this Advisory.  
 137 However, only the findings obtained from formal surveys are reported.

138 Opinion surveys were developed by the Task Force to address each clinical intervention  
 139 identified in the document. Identical surveys were distributed to two groups of respondents:  
 140 expert consultants and ASA members.

141 *Category A: Expert Opinion.* Survey responses from Task Force-appointed expert  
 142 consultants are reported in summary form in the text. A complete listing of consultant survey  
 143 responses is reported in table 1 in Appendix 3.

144 *Category B: Membership Opinion.* Survey responses from a random sample of members of  
 145 the ASA and, when appropriate, responses from members of other organizations with expertise  
 146 in the selected topics of interest are reported in summary form in the text. A complete listing of  
 147 ASA member survey responses is reported in table 2 in Appendix 3.

148 Survey responses are recorded using a 5-point scale and summarized based on median  
 149 values.\*\*

150	<i>Strongly Agree:</i>	Median score of 5 (At least 50% of the responses are 5)
151	<i>Agree:</i>	Median score of 4 (At least 50% of the responses are 4 or 4 and 5)
152	<i>Equivocal:</i>	Median score of 3 (At least 50% of the responses are 3, or no
153		other response category or combination of similar categories
154		contain at least 50% of the responses)
155	<i>Disagree:</i>	Median score of 2 (At least 50% of responses are 2 or 1 and 2)
156	<i>Strongly Disagree:</i>	Median score of 1 (At least 50% of responses are 1)

157

---

\*\* When an even number of responses are obtained, the median value is determined by calculating the arithmetic mean of the two middle values. Ties are calculated by a predetermined formula.

158 *Category C: Informal Opinion.* Open-forum testimony, Internet-based comments, letters  
159 and editorials are all informally evaluated and discussed during the development of the  
160 Advisory. When warranted, the Task Force may add educational information or cautionary  
161 notes based on this information.

162

163 **Advisory Statements.**

164 **I. Education.**

165 MRI safety education includes, but is not limited to the following topics: (1) MRI  
166 magnet hazards in zones III and IV, (2) challenges and limitations of monitoring, and (3)  
167 long-term health hazards.

168 Literature findings: There is insufficient published evidence to evaluate the effect of  
169 education regarding magnet hazards, monitoring limitations, or long-term health hazards  
170 associated with MRI. One observational study examined the potential long-term health  
171 hazards of pregnant MRI workers and pregnant non-MRI workers, and found no significant  
172 difference in the relative risk of early delivery, low birth weight or spontaneous abortions  
173 (*Category B2-E evidence*).<sup>3</sup>

174 Survey findings: The consultants and ASA members strongly agree that all  
175 anesthesiologists should have general safety education on the unique physical environment  
176 of the MRI scanner. The ASA members agree and the consultants strongly agree that all  
177 anesthesiologists should have specific education regarding the features of individual  
178 scanners within their institution. The ASA members agree and the consultants strongly  
179 agree that anesthesiologists should work in collaboration with radiologists, technologists,  
180 and physicists within their institutions to develop safety training programs.

181 **Advisory Statements for Education:**

- 182
- All anesthesiologists should have general safety education on the unique physical

183 environment of the MRI scanner, and specific education regarding the specific features of  
184 individual scanners within their institution.

185 • Education should emphasize safety for entering zones III and IV, with special  
186 emphasis on hazards in this environment and effects on monitoring capabilities.

187 • Education should address potential health hazards (*e.g.*, high decibel levels and high  
188 intensity magnetic fields), and necessary precautions to deal with the specific field strength  
189 and the safety of the MRI scanners within their institutions.

190 • Education should include information regarding ferromagnetic items (*e.g.*,  
191 stethoscopes, pens, wallets, watches, hair clips, name tags, pagers, cell phones, credit cards,  
192 batteries) and implantable devices (*e.g.*, spinal cord stimulators, implanted objects) that  
193 should not be brought into zones III and IV of the MRI suite or should be brought in with  
194 caution.

195 • Anesthesiologists should work in collaboration with radiologists, technologists, and  
196 physicists within their institutions to ensure that the above topics are included in their safety  
197 training programs.

198 • Education should include how to safely respond to code blue situations in zones III  
199 and IV, and this information should be integrated into protocols for the designated code blue  
200 team.

## 201 **II. Screening of Anesthetic Care Providers and Ancillary Support Personnel.**

202 The MRI medical director or designated technologist is responsible for access to zones  
203 III and IV. Screening of all individuals entering zone III is necessary to prevent accidental  
204 incursions of ferromagnetic materials or inadvertent exposure of personnel with foreign  
205 bodies or implanted ferromagnetic items.

206 Literature findings: The literature is insufficient to evaluate whether the screening of  
207 anesthesia care providers and ancillary support personnel improves safety in the MRI suite.

208 Survey findings: The ASA members agree and the consultants strongly agree that the  
209 anesthesiologist should work in collaboration with the MRI medical director or designee to  
210 ensure that all anesthesia team personnel entering zone III or IV have been properly  
211 screened.

### Advisory Statements for Screening of Anesthetic Care Providers and Ancillary

#### Support Personnel:

- 214 • The anesthesiologist should work in collaboration with the MRI medical director or  
215 designee (*e.g.*, safety officer) to ensure that all anesthesia team personnel entering zone III  
216 or IV have been screened for the presence of ferromagnetic materials, foreign bodies, or  
217 implanted devices.

### **III. Patient Screening.**

219 Patient screening consists of determining patient and equipment-related risks for adverse  
220 outcomes associated with MRI procedures.

221 ***Patient-related risks:*** Risks related to the patient may include age-related risks, health-  
222 related risks, and risks from foreign bodies located in or on the patient or implanted  
223 ferromagnetic items. *Age-related risks* apply to neonates or premature infants, and elderly  
224 patients. *Health-related risks* include, but are not limited to: (1) need for intensive or  
225 critical care, (2) impaired respiratory function (*e.g.*, tonsillar hypertrophy, sleep apnea), (3)  
226 changes in level of sedation, muscle relaxation, or ventilation, (4) hemodynamic instability  
227 and vasoactive infusion requirements, or (5) comorbidities that may contribute to adverse  
228 MRI effects (*e.g.*, burns or temperature increases in patients with obesity or peripheral  
229 vascular disease). *Foreign bodies* include nonmedical ferromagnetic items imbedded in the  
230 patient (*e.g.*, eyeliner tattoos, metallic intraocular fragments) or attached to the patient (*e.g.*,

231 pierced jewelry, magnetic dental keepers). *Implanted ferromagnetic items* may include such  
232 items as aneurysm clips, prosthetic heart valves, or coronary arterial stents.

233 Literature findings: One comparative study reports that neonates undergoing MRI  
234 demonstrate increased fluctuations in heart rate, blood pressure, and oxygen saturation  
235 levels compared to neonates not undergoing an MRI (*Category B1-H evidence*).<sup>4</sup> Two  
236 observational studies report that premature neonates can experience heart rate fluctuations,  
237 decreases in oxygen saturation and increases in temperature during MRI (*Category B3-H*  
238 *evidence*).<sup>5,6</sup> One case report indicates that a child with a history of prior cardiac arrest  
239 experienced a cardiac arrest during MRI (*Category B3-H evidence*).<sup>7</sup> Four observational  
240 studies<sup>8-11</sup> and two case reports<sup>12,13</sup> indicate that patients with impaired renal function are at  
241 risk of nephrogenic systemic fibrosis after gadolinium administered for MRI (*Category*  
242 *B3/4-H evidence*).

243 Case reports indicate that exposure of iron filings to the magnetic field may result in  
244 hemorrhage<sup>7,14</sup> and exposure of eyeliner tattoos may result in image artifacts, burns,  
245 swelling or puffiness<sup>7,15-17</sup> (*Category B4-H evidence*). Numerous observational studies and  
246 case reports indicate interactions with the magnetic field (*e.g.*, movements, displacements,  
247 image artifacts) and increases in temperature during MRI for ferromagnetic items such as  
248 aneurysm clips, surgical clips, prosthetic heart valves, intravenous infusion pumps, coronary  
249 arterial stents, and implanted dental magnet keepers (*Category B3/4-H evidence*).<sup>18-43</sup>

250 Survey findings: Both the consultants and ASA members strongly agree that, for every  
251 case, the anesthesiologist should communicate with the patient and radiologist or referring  
252 physician to determine whether the patient has a high-risk medical condition. In addition,  
253 they both strongly agree that if the patient presents with a high-risk medical condition the  
254 anesthesiologist should collaborate with all participants, including the referring physician,  
255 radiologist, and technologist to determine how the patient will be managed during the MRI

256 procedure. Both the consultants and ASA members agree that, for patients with acute or  
257 severe renal insufficiency, the anesthesiologist should not administer gadolinium because of  
258 the elevated risk of nephrogenic systemic fibrosis.

259 ***Equipment-related risks:*** Patient equipment-related risks include, but are not limited to:  
260 (1) physiologic monitors, (2) invasive monitors (*e.g.*, intravascular catheters), (3) intubation  
261 equipment, (4) oxygenation and ventilation equipment, and (5) pacemakers, implanted  
262 cardiofibrillators and other implanted devices (*e.g.*, deep brain stimulators, vagal or  
263 phrenic nerve stimulators, middle-ear or cochlear implants).

264 ***Literature findings:*** One case report notes that cardiac monitor leads interfered with an  
265 MRI scan (*Category B4-H evidence*).<sup>7</sup> One observational study and one case report indicate  
266 that fire or burns occurred beneath or near cardiac monitor electrodes (*Category B3/4-H*  
267 *evidence*).<sup>44,45</sup> Five case reports note that burns occurred from the looping of a temperature  
268 probe or pulse oximetry cables (*Category B4-H evidence*).<sup>46-50</sup> One observational study  
269 reports ferromagnetic components in ventilators<sup>51</sup>, and three case reports describe projectile  
270 nitrous oxide or oxygen tanks<sup>52-54</sup> (*Category B3/4-H evidence*). Additional observational  
271 studies and case reports indicate interactions of pacemakers or implanted cardioverter  
272 defibrillators with MRI scanning including, but not limited to, pacing artifacts, reed switch  
273 closure, generator movement or displacement, alterations of pacing rate, and temperature  
274 increases (*Category B3/4-H evidence*).<sup>7,55-84</sup> Two observational studies report palpitations,  
275 rapid heart rate and discomfort at the pacemaker pocket after MRI.<sup>75,85</sup> Finally, two cases of  
276 cardiac arrest are reported in patients with pacemakers during or after an MRI scan; in one  
277 case, the patient died (*Category B4-H evidence*).<sup>7,57</sup>

278 Three observational studies report image artifacts when MRI is performed on patients  
279 with neurostimulators, infusion pumps, implantable spinal fusion stimulators, or cochlear  
280 implants (*Category B3-H evidence*).<sup>86-88</sup> Six observational studies report increased

281 temperatures in patients with deep brain stimulators, neurostimulators, or spinal cord  
282 stimulators<sup>89-94</sup> and three report displacement of leads, pulse generators or other  
283 components of deep brain stimulators or middle ear prostheses during MRI scans (*Category*  
284 *B3-H evidence*).<sup>95-97</sup>

285 Survey findings: Both the consultants and ASA members agree that, for every case, the  
286 anesthesiologist should communicate with the radiologist or referring physician to  
287 determine whether the patient requires equipment that may pose a risk during the scan. In  
288 addition, they agree that anesthesiologists should determine the safety and effectiveness of  
289 the equipment needed by the patient during the procedure for each MRI location. Further,  
290 the consultants and ASA members strongly agree that anesthesiologists should work with  
291 their institutions to properly identify and label anesthesia-related equipment according to  
292 convention for each MRI scanner. The ASA members agree and the consultants strongly  
293 agree that care should be taken to assure that anesthesia equipment does not interfere with  
294 image acquisition or quality. Both the consultants and ASA members agree that, in general,  
295 MRI should not be performed on patients with implanted electronic devices. Finally, both  
296 the consultants and ASA members strongly agree that, when MRI is considered essential by  
297 the referring physician and consulting radiologist, a plan for managing patients with  
298 implanted electronic devices during the scan should be developed in collaboration with the  
299 referring physician, medical director or on-site radiologist, and other appropriate  
300 consultants.

301 **Advisory Statements for Patient Screening:**

- 302 • For every case, the anesthesiologist should communicate with the patient, referring  
303 physician, and radiologist to determine whether the patient: (1) presents with a high-risk  
304 medical condition (*e.g.*, neonatal status or prematurity, intensive or critical care status,  
305 impaired respiratory function, hemodynamic instability and vasoactive infusion

306 requirements, or comorbidities such as obesity and peripheral vascular disease), (2) requires  
307 equipment (*e.g.*, physiologic or invasive monitors; intubation, oxygenation or ventilation  
308 equipment); (3) has implanted devices (*e.g.*, pacemakers, cardioverter defibrillators, or nerve  
309 stimulators), (4) has been screened for the presence of implanted ferromagnetic items (*e.g.*,  
310 surgical clips, prosthetic heart valves), and (5) has been screened for the presence of  
311 *imbedded* foreign bodies (*e.g.*, orbital iron filings, eyeliner tattoos).

312 • The anesthesiologist should communicate with the technologist to ensure that the  
313 patient has been screened for the presence of foreign bodies *on the patient* (*e.g.*, pierced  
314 jewelry, rings) prior to entering zone III.

315 • If a patient presents with a high-risk medical condition, the anesthesiologist should  
316 collaborate with all participants, including the referring physician, radiologist and  
317 technologist, to determine how the patient will be managed during the MRI procedure.  
318 Anticipated changes in level of sedation, muscle relaxation, or ventilation may also place a  
319 patient in a high-risk situation.

320 • For patients with acute or severe renal insufficiency, the anesthesiologist should not  
321 administer gadolinium because of the elevated risk of nephrogenic systemic fibrosis.<sup>††</sup>

322 • Anesthesiologists should work with their institutions to properly identify and label  
323 anesthesia-related equipment according to convention (safe, unsafe, or conditional) for each  
324 MRI scanner.<sup>‡‡</sup>

325 • For each MRI location, anesthesiologists should determine the safety and  
326 effectiveness of the equipment needed by the patient during the procedure. In addition, care

---

<sup>††</sup> See United States Food and Drug Administration alert:  
[www.fda.gov/Cder/Drug/InfoSheets/HCP/gcca\\_200705.htm](http://www.fda.gov/Cder/Drug/InfoSheets/HCP/gcca_200705.htm)

<sup>‡‡</sup> Equipment is categorized as safe, unsafe, or conditional for use in the MRI environment. MRI “safe” equipment is identified by the American Society for Testing and Materials as having no ferromagnetic parts or radiofrequency interference. MRI “unsafe” equipment is identified as having ferromagnetic parts or being affected by radiofrequency interference. MRI “conditional” equipment may be safe in certain locations of the suite depending on gauss line locations, but cannot be identified as having no ferromagnetic parts (see American Society for Testing and Materials Practice Standards F2503, F2119, and F2052, [www.astm.org](http://www.astm.org)).

327 should be taken to ensure that equipment does not interfere with image acquisition or  
328 quality.

329 • The Task Force believes that cardiac pacemakers and implantable cardioverter-  
330 defibrillators are generally contraindicated for MRI. These devices pose an extreme hazard  
331 in this environment, and may be life-threatening within the 5 gauss line.<sup>§§</sup> When MRI is  
332 considered essential by the referring physician and consulting radiologist, a plan for  
333 managing these patients during the scan should be developed in collaboration with the  
334 ordering physician, medical director or on-site radiologist and other appropriate consultants  
335 (*e.g.*, the patient's pacemaker specialist or cardiologist, the diagnostic radiologist, and the  
336 device manufacturer).<sup>\*\*\*</sup>

337 • Other implanted electronic devices also pose a hazard in the MRI environment.  
338 These devices and associated wiring may transfer energy during the MRI scan, causing  
339 tissue damage, malfunction of the device, image artifacts, and device displacement. MRI  
340 may be performed on a limited basis for patients with certain implanted electronic devices  
341 (*e.g.*, deep brain stimulators, vagal nerve stimulators, phrenic nerve stimulators, wire-  
342 containing thermolysis catheters, or cochlear implants). In consultation with the  
343 referring physician, the radiologist responsible for the procedure, and the neurosurgeon, the  
344 anesthesiologist should ensure that the presence of the device has been noted and  
345 determined to be MRI safe/conditional prior to imaging of these patients.

#### 346 **IV. Preparation.**

347 Preparation consists of determining and implementing an individualized anesthetic plan  
348 before the MRI procedure begins. In addition to the anesthetic plan, preparation includes a

---

<sup>§§</sup> In 2011, the FDA approved the use of pacemakers and leads as MRI conditional for certain patients, scans of certain parts of the body, and under certain scanning parameters. The subsequent development and clinical application of MRI-safe pacemakers and ICDs may be addressed in a future revision of this Advisory.

<sup>\*\*\*</sup> American Society of Anesthesiologists: Practice advisory for the perioperative management of patients with cardiac rhythm management devices: pacemakers and implantable cardioverter-defibrillators. ANESTHESIOLOGY 2005; 103:186-198.

349 plan for optimal positioning of equipment and personnel in the MRI suite during the  
350 procedure.

351 Literature findings: The literature is insufficient to determine whether active  
352 preparation or pre-MRI planning reduces the frequency of adverse events. One case report  
353 indicates that misinformation about the type of aneurysm clip resulted in intracerebral  
354 hemorrhage and death, and a second case report indicates that a lack of communication  
355 among physicians caring for a pacemaker patient resulted in the death of the patient  
356 (*Category B4-H evidence*).<sup>31,98</sup>

357 Survey findings: Both the consultants and ASA members strongly agree that, for every  
358 case, the anesthesiologist should prepare, with support personnel a plan for providing  
359 optimal anesthetic care within the special environment of the MRI suite. They both strongly  
360 agree that the anesthesiologist should communicate with the radiology personnel to  
361 determine the requirements of the scan. The ASA members agree and the consultants  
362 strongly agree that the anesthesiologist should collaborate with the MR technologist and/or  
363 facility biomedical engineer to determine and demarcate the optimal and safe location of  
364 movable equipment in relation to the gauss lines within the MRI suite. They both strongly  
365 agree that, because line of sight within the bore will vary depending on the facility, the  
366 anesthesiologist should choose a location or position for optimal patient observation and  
367 vigilance during delivery of care, whether in zone III or IV. Finally, they both strongly  
368 agree that the anesthesiologist should prepare a plan for rapidly summoning additional  
369 personnel in the event of an emergency.

370 **Advisory Statements for Preparation:**

371 • For every case, the anesthesiologist should prepare, with support personnel, a plan  
372 for providing optimal anesthetic care within the special environment of the MRI suite. In  
373 addition to addressing the medical needs of the patient, features of the plan should include:

374 (1) requirements of the scan and personnel needs, (2) positioning of equipment, (3) special  
375 requirements or unique issues of patient or imaging study, (4) positioning of the  
376 anesthesiologist and the patient, and (5) planning for emergencies.

377 • The anesthesiologist should communicate with the radiology personnel to determine  
378 the requirements for the scan (*e.g.*, duration of the scan, position of the patient or area of the  
379 body in the scanner, positioning of receiver coils, need for periods of paused respiration).

380 The anesthesiologist should communicate with other anesthesia team members regarding  
381 individual roles for anesthetic care.

382 • The anesthesiologist should collaborate with the MR technologist and/or facility  
383 biomedical engineer to determine and demarcate the optimal and safe location of movable  
384 equipment in relation to the gauss lines within the MRI suite.

385 • Because line of sight within the bore will vary depending on the facility, the  
386 anesthesiologist should choose a location or position for optimal patient observation and  
387 vigilance during delivery of care, whether in Zone III or IV. In particular, anesthesiologists  
388 should have: (1) a clear line of sight of the patient and physiologic monitors, whether by  
389 direct observation or by video camera, (2) anesthetic delivery equipment located for optimal  
390 control of anesthetic depth and rapid intervention, and (3) access to hospital information  
391 systems integral to patient care. In preparing for positioning, the anesthesiologist should  
392 take into account potential electromagnetic and auditory hazards.

393 • Anesthesiologists should prepare a plan for rapidly summoning additional personnel  
394 in the event of an emergency. Because the MRI suite is frequently located in an isolated  
395 area of the facility, the anesthesiologist should ensure that (1) emergency equipment and  
396 drugs are immediately accessible, (2) emergency communication (*e.g.*, phone or code  
397 button) is immediately available, and (3) an evacuation plan is in place, including an

398 appropriate location outside the scan room (zone IV) for resuscitation. This location should  
 399 be complete with physiologic monitors, oxygen, suction, and other appropriate resuscitation  
 400 equipment. Monitoring requirements, airway management, and emergency preparedness  
 401 are additional features that should be included in the preparation and planning for an MRI  
 402 scan, and are addressed in section V below.

403 **V. Patient management during MRI.**

404 Features of safe patient management during MRI procedures include: (1) monitoring, (2)  
 405 anesthetic care, (3) airway management, and (4) management of emergencies.

406 ***Monitoring:*** Safe monitoring conditions include: (1) the use of MRI-safe/conditional  
 407 monitors, (2) remote monitoring, and (3) compliance with ASA standards.<sup>99</sup>

408 ***Literature findings:*** Three observational studies indicate that the use of MRI compatible  
 409 monitoring equipment resulted in no radiofrequency interference, interruptions in scanning,  
 410 or artifacts (*Category B3-B evidence*).<sup>100-102</sup> Five observational studies demonstrate that  
 411 remote monitoring for heart rate, blood pressure, auscultation, respiration, and chest wall  
 412 movement can be performed safely and effectively (*Category B3-B evidence*).<sup>101,103-106</sup> One  
 413 observational study reported that compliance with the ASA “Standards for Basic Anesthesia  
 414 Monitoring can be obtained, provided that the monitoring equipment is properly tested prior  
 415 to an MRI (*Category B3-E evidence*).”<sup>107</sup>

416 ***Survey findings:*** The consultants and ASA members both strongly agree that MRI  
 417 patients should be monitored in a manner consistent with the ASA “Standards for Basic  
 418 Anesthesia Monitoring.” In addition, they both strongly agree that (1) anesthesiologists  
 419 should be familiar with the expected limitations of available monitoring equipment, (2) the  
 420 anesthesiologist should make sure that all monitors used in zone IV are safe/conditional for  
 421 the scan, and (3) a monitor should be available to view vital signs from zone III when the  
 422 anesthesia care provider is not in zone IV.

423 **Advisory Statements for Monitoring:**

424 • MRI patients should be monitored in a manner consistent with the ASA “Standards  
 425 for Basic Anesthesia Monitoring.” Anesthesiologists should be familiar with the expected  
 426 limitations of available monitoring equipment. The Task Force notes that information from  
 427 electrocardiograms may be limited due to superimposed voltages from blood flow in the  
 428 high magnetic field (*e.g.*, ST segment interpretation may be unreliable, even with highly-  
 429 filtered monitors).

430 • The anesthesiologist should make sure that all monitors used in zone IV are  
 431 safe/conditional for the scan.

432 • A monitor should be available to view vital signs from zone III when the anesthesia  
 433 care provider is not in zone IV.

434 • Additional care should be taken in positioning ECG and other monitor leads to  
 435 eliminate burns, even with non-ferromagnetic leads.

436 ***Anesthetic Care:***

437 **Literature findings:** Observational studies report a high rate of success in imaging of  
 438 moderately sedated patients (*Category B3-B evidence*)<sup>108-115</sup> However, imaging failures or  
 439 motion artifacts may still occur (*Category B3-H evidence*).<sup>116-119</sup> Observational studies  
 440 report a high rate of successful imaging in patients receiving deep sedation or light  
 441 anesthesia, with low rates of motion artifacts (*Category B3-B evidence*).<sup>120-124</sup> One RCT  
 442 reports equivocal findings for scan repeats when light anesthesia is compared with general  
 443 anesthesia (*Category A3-E evidence*).<sup>125</sup> Observational studies and case reports also  
 444 indicate that respiratory depression, oxygen desaturation, bronchospasm, drowsiness,  
 445 agitation and vomiting may occur with moderate sedation or light anesthesia (*Category*  
 446 *B3/4-H evidence*).<sup>100,109, 115-117,119,120,122-124,126-142</sup> The Task Force believes that automated

447 apnea monitoring (by detection of exhaled carbon dioxide or other means) may decrease  
448 risks during both moderate and deep sedation.

449 Survey findings: Both the consultants and ASA members strongly agree that, in general,  
450 because MRI is a non-painful procedure, lighter levels of anesthesia may be appropriate,  
451 recognizing that institutional circumstances, patient characteristics, and anesthesiologist  
452 preference may warrant more aggressive airway management and deeper anesthetic levels.  
453 They both strongly agree that anesthesiologists should ensure that patients who receive  
454 moderate or deep sedation are monitored in a manner consistent with their institution's  
455 protocol for monitoring similarly sedated patients elsewhere in the facility. In addition, they  
456 both strongly agree that equipment and drugs for anesthetic care in the MRI suite should  
457 mirror what is available in the operating room. Both the consultants and ASA members are  
458 equivocal that, when an MRI-safe/conditional anesthesia machine is not available,  
459 inhalation anesthetics may be administered from an anesthesia machine inside zone III *via*  
460 an elongated circuit through a wave guide. Finally, both the consultants and ASA members  
461 agree that, if total intravenous anesthesia is used, it should be administered by using: (1)  
462 MRI-safe/conditional pumps in zone IV, (2) traditional (*i.e.*, MRI-unsafe) pumps in zone III  
463 with intravenous tubing passed through a wave-guide, or (3) periodic bolus injections in  
464 either zones III or IV.

465 **Advisory Statements for Anesthetic Care:**

466 • Although lighter levels of anesthesia may be appropriate during an MRI scan, the  
467 anesthesiologist should be aware that these lighter levels may result in airway complications  
468 (*e.g.*, laryngospasm, coughing or other airway compromise) which may necessitate  
469 interruption of the scan for urgent treatment and alteration of anesthetic depth. Institutional  
470 circumstances, patient characteristics, and anesthesiologist preference may warrant more  
471 aggressive airway management and deeper anesthetic levels.

472           • Anesthesiologists should ensure that patients who receive moderate or deep sedation  
473 are monitored in a manner consistent with their institution’s protocol for monitoring  
474 similarly sedated patients elsewhere in the facility.

475           • Monitoring of exhaled carbon dioxide should be considered for all patients receiving  
476 deep sedation and for patients whose ventilation cannot be directly observed during  
477 moderate sedation.<sup>†††</sup> The Task Force cautions that, because ventilation and oxygenation  
478 are separate though related physiological processes, monitoring oxygenation by pulse  
479 oximetry is not a substitute for monitoring ventilatory function.

480           • Equipment and drugs for anesthetic care in the MRI suite should mirror what is  
481 available in other anesthetizing locations including: (1) an integrated anesthesia machine,  
482 medical gases, and waste anesthesia gas disposal or gas scavenging, when inhalational  
483 anesthesia is administered, (2) suction, (3) adequate electrical outlets and lighting, and (4)  
484 storage areas for equipment and drugs. The Task Force recognizes that physical plant  
485 variability exists among institutions.<sup>‡‡‡</sup>

486           • Equipment used in the MRI suite should be appropriate for the age and size of the  
487 patient.

488           • MRI-safe/conditional anesthesia machines are always preferred for use in an MRI  
489 facility.<sup>§§§</sup> However, when an MRI-safe/conditional anesthesia machine is not available,  
490 inhalational anesthetics can be administered from an anesthesia machine inside zone III *via*

---

<sup>†††</sup> See “American Society of Anesthesiologists: Practice guidelines for sedation and analgesia by non-anesthesiologists: an updated report. ANESTHESIOLOGY 2002; 96:1004-1017.” When light general anesthesia is administered, refer to the American Society of Anesthesiologists: Standards for Basic Anesthetic Monitoring (last amended October 20, 2010, effective date July 1, 2011).

<sup>‡‡‡</sup> When remodeling or building a new facility, input from the anesthesiologist is critical.

<sup>§§§</sup> An MRI facility that is newly built or that undergoes a major renovation should have an MRI safe/conditional anesthesia machine.

491 an elongated circuit through a wave guide.<sup>\*\*\*\*</sup> Although this method of anesthetic delivery  
492 was commonplace prior to the commercial manufacture of MRI-safe/conditional anesthesia  
493 machines, this practice is inherently cumbersome and may be prone to more possibilities for  
494 mishaps than the use of an anesthesia machine specifically designed for the MRI  
495 environment.

496 • Alternatively, if total intravenous anesthesia (TIVA) is used, it should be  
497 administered by using: (1) MRI-safe/conditional pumps in zone IV, (2) traditional (*i.e.* MRI  
498 unsafe) pumps in zone III with intravenous tubing passed through a wave guide, or (3)  
499 periodic bolus injections in either zones III or IV. Although an anesthesia machine may not  
500 be required for the administration of TIVA, there must be equipment immediately available  
501 for the administration of positive pressure ventilation with oxygen.

502 ***Airway Management:*** Unique features of airway management during an MRI scan  
503 include: (1) the limited accessibility of the patient's airway and (2) the difficulty of  
504 conducting visual and auditory assessments of the patient.

505 ***Literature findings:*** The literature is insufficient to assess the management of airway  
506 problems (*e.g.*, obstruction, secretions, laryngospasm, apnea and hypoventilation) during an  
507 MR scan. In addition, the literature is insufficient to assess whether the use of a tracheal  
508 tube or laryngeal mask airway improves outcomes for patients at risk of airway compromise  
509 during MRI.

510 ***Survey findings:*** Both the consultants and ASA members strongly agree that the  
511 anesthesiologist should have an advance plan in place to deal with instrumentation of the  
512 airway and common airway problems when patients are in an MRI environment. Both the  
513 consultants and ASA members strongly agree that, if the patient is at risk for airway

---

<sup>\*\*\*\*</sup> A wave guide is a copper-lined conduit with a specific length and diameter that maintains RF isolation of the magnet room installed during construction of the MRI suite. Wires or conducting material act as an antenna and should not be passed through a wave guide.

514 compromise, more aggressive airway management should be instituted because the patient's  
515 airway may be less accessible when the patient is in the scanner. Both the consultants and  
516 ASA members strongly agree that (1) complex airway management (*e.g.*, fiberoptic  
517 intubation) should be performed in a controlled environment outside of zone IV, (2)  
518 alternative airway devices should be immediately available in the MRI suite, and (3) suction  
519 equipment should be immediately accessible to the patient's airway at all times.

520 **Advisory Statements for Airway Management:**

- 521 • The anesthesiologist should have an advance plan in place to deal with  
522 instrumentation of the airway and common airway problems (*e.g.*, obstruction, secretions,  
523 laryngospasm, apnea and hypoventilation) when patients are in an MRI environment.
- 524 • If the patient is at risk for airway compromise, more aggressive airway management  
525 (*e.g.*, use of a tracheal tube or LMA) should be instituted because the patient's airway may  
526 be less accessible when the patient is in the scanner.
- 527 • Complex airway management (*e.g.*, fiberoptic intubation) should be performed in a  
528 controlled environment outside of zone IV.
- 529 • Alternative MRI safe/conditional airway devices should be immediately available in  
530 the MRI suite. Suction equipment should be immediately accessible to the patient's airway  
531 at all times.

532 ***Management of Emergencies:*** Emergencies in the MR suite include (1) medical  
533 emergencies (*e.g.*, cardiopulmonary arrest) and (2) environmental emergencies (*e.g.*,  
534 quench, fire, projectiles). The remote location of the scanner within the facility may delay  
535 response of support personnel or availability of equipment during an emergency.

536 **Literature findings:** The literature is insufficient regarding the management of medical  
537 emergencies (*e.g.*, cardiopulmonary arrest) or quench in the MR suite. One case report

538 indicates that a fire occurring on the patient was managed by extinguishing the flames,  
539 discontinuing the scan, and immediately removing the patient from the bore (*Category B4*  
540 *evidence*).<sup>45</sup> Two case reports of projectile nitrous oxide or oxygen tanks indicate that the  
541 emergency was managed by removing patients from zone IV and instituting a controlled  
542 quench (*Category B4 evidence*).<sup>53,54</sup>

543 Survey findings: Both the consultants and ASA members strongly agree that when a  
544 patient has a medical emergency in the MRI scanner, the following should occur: (1)  
545 initiate CPR, when needed, while immediately removing the patient from zone IV, (2) call  
546 for help, and (3) transport the patient to a previously designated safe location in proximity to  
547 the MRI suite. In addition, they both strongly agree that the designated safe location should  
548 contain the following resuscitation equipment: (1) a defibrillator, (2) vital signs monitors,  
549 and (3) a code cart that includes resuscitation drugs, airway equipment, oxygen, and suction.  
550 The consultants and ASA members both strongly agree that when a fire occurs in the MRI  
551 suite, team members should perform their pre-assigned fire management tasks as quickly as  
552 possible, in accordance with the ASA “Practice Advisory for the Prevention and  
553 Management of Operating Room Fires.”<sup>143</sup> The ASA members agree and the consultants  
554 strongly agree that, when a quench occurs, team members should perform their institution’s  
555 protocol in reaction to this occurrence. In addition, the ASA members agree and the  
556 consultants strongly agree that, when a quench occurs, if possible (1) immediately remove  
557 the patient from zone IV, and (2) immediately administer oxygen to the patient. Finally,  
558 both the consultants and ASA members agree that, since powerful static magnetic fields  
559 may persist after a quench or fire, emergency response personnel should be restricted from  
560 entering zone IV.

561 Advisory Statements for Management of Emergencies:

562           • Medical emergencies may be difficult to manage while the patient is in the MRI  
563 scanner.

564           • When a patient has a medical emergency (*e.g.*, cardiopulmonary arrest) in the MRI  
565 scanner, the following should occur: (1) immediately remove the patient from Zone IV  
566 while initiating CPR, if indicated, (2) call for help, and (3) transport the patient to a  
567 previously designated safe area for resuscitation that is not in zone IV. This location should  
568 be as close to zone IV as possible so as not to delay resuscitation efforts, and should contain  
569 the following resuscitation equipment: a defibrillator, vital signs monitors, and a code cart  
570 that includes resuscitation drugs, airway equipment, oxygen, and suction.

571           • When a fire occurs in the MRI suite, team members should perform their pre-  
572 assigned fire management task as quickly as possible, in accordance with the ASA Practice  
573 Advisory for the Prevention and Management of Operating Room Fires.<sup>143</sup> If a team  
574 member cannot rapidly perform his or her task in the predetermined order, other team  
575 members should perform their tasks *without waiting*. When a team member has completed  
576 a pre-assigned task, he or she should help other members perform tasks that are not yet  
577 complete.

578           • In the case of projectile emergencies, team members should perform their  
579 institution's protocol in reaction to this occurrence. If possible, immediately remove the  
580 patient from zone IV and discontinue the scan. If the patient is injured, proceed with  
581 medical emergency management as indicated above.

582           • A controlled quench may be necessary in order to remove the patient from the bore.  
583 A quench occurs when a superconducting magnet turns resistive and catastrophically  
584 releases all of the stored energy as heat, boiling off the stored cryogenics as gas. The most  
585 common cause of quench is an intentional shutdown of the magnet for a life-threatening

586 emergency. Quench may also be the consequence of an unintentional shutdown. If not  
587 properly vented, a quench can result in the complete dissipation of oxygen in zone IV,  
588 risking hypoxia to the patient and MRI personnel. In addition, entrance to zone IV may not  
589 be possible due to high pressure caused by escaping gases, making it impossible to open the  
590 door into zone IV. When a quench occurs, team members should perform their institution's  
591 protocol in reaction to this occurrence. If possible, (1) immediately remove the patient from  
592 zone IV and (2) immediately administer oxygen to the patient.

593 • Powerful static magnetic fields may persist after a quench, and therefore the usual  
594 precautions apply when entering zone IV. Emergency response personnel should be  
595 restricted from entering zone IV during any environmental emergency because of the  
596 persistent magnetic field.

#### 597 **VI. Post-procedure care.**

598 Literature findings: The literature is insufficient to determine whether post-procedure  
599 care consistent with that provided for other areas of the institution reduces the frequency of  
600 adverse events.

601 Survey findings: The ASA members agree and the consultants strongly agree that the  
602 anesthesiologist should collaborate with the radiologist and other staff in the postanesthetic  
603 care of the patient. Finally, both the consultants and ASA members strongly agree that: (1)  
604 patients receiving sedation or anesthesia within the MRI suite should have access to  
605 postanesthetic care consistent with that provided in other areas of the institution, (2) in all  
606 situations, intensive care and recovery areas should include access to vital signs monitors,  
607 oxygen, suction, and trained personnel, and (3) patients should be provided written  
608 discharge instructions.

#### 609 Advisory statements for post-procedure care:

610 • The anesthesiologist should collaborate with the radiologist and other staff in the

PRACTICE ADVISORY

611 postanesthetic care of the patient.

612       • Patients receiving sedation or anesthesia within the MRI suite should have access to  
613 postanesthetic care consistent with that provided in other areas of the institution, including  
614 transport to other recovery rooms, dedicated intensive care, or recovery areas within the  
615 MRI suite.

616       • In all situations, intensive care and recovery areas should include access to vital sign  
617 monitors, oxygen, suction, resuscitation equipment, and trained personnel. †††

618       • Patients should be provided oral and written discharge instructions.

DRAFT

---

††† When remodeling or building a new facility, an attempt should be made to locate recovery and resuscitation in proximity to the MRI suite.

**References**

1. Kanal E, Borgstede JP, Barkovich AJ, Bell C, Bradley WG, Felmlee JP, Froelich JW, Kaminski EM, Keeler EK, Lester JW, Scoumis EA, Zaremba LA, Zininger MD: American College of Radiology White Paper on MR Safety. *AJR Am J Roentgenol* 2002; 178:1335-1347
2. Kanal E, Barkovich AJ, Bell C, Bradler WG Jr, Froelich JW, Gilk T, Gimbel JR, Gosbee J, Kuhie-Kaminski E, Lester JW Jr, Nuenhuis J, Parag Y, Schaefer DJ, Sebek-Scoumis EA, Weinreb J, Zaremba LA, Wilcox P, Lucey L, Sass N; ACR Blue Ribbon Panel on MR Safety: ACR guidance document for safe MR practices: 2007. *AJR Am J Roentgenol* 2007; 188:1447-1474
3. Kanal E, Gillen J, Evans JA, Savitz DA, Shellock FG: Survey of reproductive health among female MR workers. *Radiology* 1993; 187:395-399
4. Philbin MK, Taber KH, Hayman LA: Preliminary report: changes in vital signs of term newborns during MR. *AJNR Am J Neuroradiol* 1996; 17:1033-1036
5. Battin M, Maalouf EF, Counsell S, Herligy A, Hall A, Azzopardi D, Edwards AD: Physiologic stability of preterm infants during magnetic resonance imaging. *Early Hum Dev* 1998; 52:101-110
6. Taber KH, Hayman LA, Northrup SR, Maturi L: Vital sign changes during infant magnetic resonance examinations. *J Magn Reson Imaging* 1998; 8:1252-1256
7. Gangarosa RE, Minnis JE, Nobbe J, Praschan D, Genberg RW: Operational safety issues in MRI. *Magn Reson Imag* 1987;5:287-292
8. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA: Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. *AJR Am J Roentgenol* 2007; 188:586-592
9. Grobner T: Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? *Nephrol Dial Transplant* 2006; 21:1104-1108
10. Khurana A, Runge VM, Narayanan M, Greene JF Jr., Nickel AE: Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection. *Invest Radiol* 2007; 42:139-145
11. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS: Nephrogenic systemic fibrosis: suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging. *J Am Soc Nephrol* 2006; 17:2359-2362
12. Dharnidharka VR, Wesson SK, Fennel RS: Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients. *Pediatr Nephrol* 2006; 22:1395
13. Thakral C, Alhariri J, Abraham JL: Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. *Contrast Media Mol Imaging* 2007; 2:199-205
14. Kelly WM, Paglen PG, Pearson JA, San Diego AG, Soloman MR: Ferromagnetism of intraocular foreign body causes unilateral blindness after MR study. *AJNR Am J Neuroradiol* 1986; 7:243-245
15. Jackson JG, Acker JD: Permanent eyeliner and MR imaging. *AJR Am J Roentgenol* 1987; 49:1080
16. Lund G, Nelson JD, Wirtschafter JD, Williams PA: Tattooing of eyelids; magnetic resonance imaging artifacts. *Ophthalmol Surg* 1986; 17:550553
17. Wagle WA, Smith M: Tattoo-induced skin burn during MR imaging. *AJR Am J Roentgenol* 2000; 174:1795

PRACTICE ADVISORY

18. Applebaum E, Valvassori G: Further studies on the effects of magnetic resonance fields on middle ear implants. *Ann Otol Rhinol Laryngol* 1990; 99:801-804
19. Barrafato D, Henkelman RM: Magnetic resonance imaging and surgical clips. *Can J Surg* 1984; 27:509-512
20. Becker RL, Forfray JF, Teitelbaum GP, Bradley WG Jr, Jacobs JB, Wacaser L, Rieman RL: MR imaging in patient with intracranial aneurysm clips. *AJNR Am J Neuroradiol* 1988; 9:885-889
21. Brown MA, Carden JA, Coleman RE, McKinney R, Spicer LD: Magnetic field effects on surgical ligation clips. *Magn Reson Imaging* 1987; 5:443-453
22. Chou C-K, McDougall JA, Chan KW: RF heating of implanted spinal fusion stimulator during magnetic resonance imaging. *IEEE Trans Biomed Eng* 1997; 44:367-372
23. Davis PL, Crooks L, Arakawa M, McRii R, Kaufman L, Margulis AR: Potential hazards of NMR imaging: heating effects of changing magnetic fields and RF fields on small metallic implants. *AJR Am J Roentgenol* 1981; 137:857-860
24. Dujovny M, Kossovsky N, Kossowsky R, Valdivia R, Suk JS, Diaz FG, Berman K, Cleary W: Aneurysm clip motion during magnetic resonance imaging: in vivo experimental study with metallurgical factor analysis. *Neurosurgery* 1985; 17:543-548
25. Edwards MB, Taylor KM, Shellock FG: Prosthetic heart valves: evaluation of magnetic field interaction, heating and artifacts at 1.5 T. *J Magn Reson Imaging* 2000;12:363-369
26. Gegauff AF, Laurell KA, Thavendrarajah A, Rosenstiel SF: A potential MRI hazard: forces on dental magnet keepers. *J Oral Rahab* 1990; 17:403-410
27. Hartnell GG, Spence L, Hughe LA, Cohen MC, Saouf R, Buff B: Safety of MR imaging in patients who have retained metallic materials after cardiac surgery. *Am J Roentgenol* 1997; 168:1157-1159
28. Hug J, Nagel E, Bornstedt A, Schnackenburg B, Oswald H, Fleck E: Coronary arterial stents: safety and artifacts during MR imaging. *Radiology* 2000;216:781-787
29. Kaste S, Laningham F, Stazzone M, Brown SD, Emery K, Newman B, Racadio J, Estroff J, Brill P, Mendelson KL, Slovis TL, Frush D: Safety in pediatric MR and cardiac CT: results of a membership survey of the Society for Pediatric Radiology-2006. *Pediatr Radiol* 2007; 37:409-412
30. Kean DM, Worthington BS, Firth JL, Hawkes RC: The effect of magnetic resonance imaging on different types of microsurgical clips. *J Neurol Neurosurg Psychiatry* 1985; 48:286-287
31. Klucznik R, Carrier D, Pyka R, Haid R: Placement of a ferromagnetic intracerebral aneurysm clip in a magnetic field with a fatal outcome. *Radiology* 1993; 187:855-856
32. Konings MK, Bartels LW, Smits HFM, Bakker CJG: Heating around intravascular guidewires by resonating RF waves. *J Magn Reson Imaging* 2000; 12:79-85
33. Laakman RW, Kaufman B, Han JS, Nelson AD, Clampitt M, O'Block AM, Haaga JR, Alfidri RJ: MR imaging in patients with metallic implants. *Radiology* 1985; 157:711-714
34. Moscatel MA, Shellock FG, Morisoli SM: Biopsy needles and devices: assessment of ferromagnetism and artifacts during exposure to a 1.5 T MR system. *J Magn Reson Imaging* 1995; 5:369-372
35. Pruefer D, Kalden P, Schreiber W, Dahm M, Buerke M, Thelen M, Oelert H: In vitro investigation of prosthetic heart valves in magnetic resonance imaging: evaluation of potential hazards. *J Heart Valve Dis* 2001; 10:410-414
36. Romner B, Olsson M, Ljunggren B, Holtas S, Saveland H, Brandt L, Persson B: Magnetic resonance imaging and aneurysm clips. *J Neurosurg* 1989; 70:426-431

37. Shellock FG: Prosthetic heart valves and annuloplasty rings: assessment of magnetic field interactions, heating, and artifacts at 1.5 Tesla. *J Cardiovasc Magn Reson* 2001; 3:317-324
38. Shellock FG: Biomedical implants and devices: assessment of magnetic field interactions with a 3.0-Tesla MR system. *J Magn Reson Imaging* 2002; 16:721-732
39. Shellock F, Crues J: High field strength MR imaging and mettalic biomedical implants: an ex vivo evaluation of deflection forces. *AJR Am J Roentgenol* 1988; 151:389-392
40. Soulon R, Budinger T, Higgins C: Magnetic resonance imaging of prosthetic heart valves. *Radiology* 1985; 154:705-707
41. Teitelbaum GP, Lin MC, Watanabe AT, Norfray JF, Young TI, Bradley WG, Jr.: Ferromagnetism and MR imaging: safety of carotid vascular clamps. *AJNR Am J Neuroradiol* 1990; 11:267-272
42. Von Roemeling R, Lanning RM, Eames FA: MR imaging of patients with implanted drug infusion pumps. *J Magn Reson Imaging* 1991; 1:77-81
43. Wichmann W, Von Ammon K, Fink U, Weik T, Yasargil GM: Aneurysm clips made of titanium: magnetic characteristics and artifacts in MR. *AJNR Am J Neuroradiol* 1997; 18:939-944
44. Dempsey MF, Condon B: Thermal injuries associated with MRI. *Clin Radiol* 2001; 56:457-465
45. Kugel H, Bremer C, Püschel M, Fischbach R, Lenzen H, Tombach B, Van Aken H, Heindel W: Hazardous situation in the MR bore: induction in ECG leads causes fire. *Eur Radiol* 2003; 13: 690-694
46. Anonymous: ECRI: The safe use of equipment in the magnetic resonance environment. *Health Devices* 2001; 30:421-444
47. Bashein G, Syrory B: Burns associated with pulse oximetry during magnetic resonance imaging. *Anesthesiology* 1991; 75:382-383
48. Brown TR, Goldstein B, Little J: Severe burns resulting from magnetic resonance imaging with cardiopulmonary monitoring. Risks and relevant safety precautions. *Am J Phys Med Rehabil* 1993; 72:166-167
49. Hall SC, Stevenson GW, Suresh S: Burn associated with temperature monitoring during magnetic resonance imaging. *Anesthesiology* 1992; 76:152
50. Shellock FG, Slimp GL: Severe burn of the finger caused by using a pulse oximeter during MR imaging. *AJR Am J Roentgenol* 1989; 153:1105
51. Williams EJ, Jones NS, Carpenter TA, Bunch CS, Menon DK: Testing of adult and paediatric ventilators for use in a magnetic resonance imaging unit. *Anaesthesia* 1999; 54:969-974
52. Anonymous: ECRI hazard report: patient death illustrates the importance of adhering to safety precautions in magnetic resonance environments. *Health Devices* 2001; 30:311-314
53. Chaljub G, Kramer LA, Johnson RF III, Singh H, Crow WN: Projectile cylinder accidents resulting from the presence of ferromagnetic nitrous oxide or oxygen tanks in the MR suite. *AJR Am J Roentgenol* 2001;177:27-30
54. Colletti PM: Size "H" oxygen cylinder: accidental MR projectile at 1.5 Tesla. *J Magn Reson Imaging* 2004; 19:141-143
55. Achenbach S, Moshage W, Diem B, Bieberle T, Schibgilla V, Bachmann K: Effects of magnetic resonance imaging on cardiac pacemakers and electrodes. *Am Heart J* 1997; 134:467-473

56. Anfinssen OG, Berntsen RF, Aass H, Kongsgaard E, Amlie JP: Implantable cardioverter defibrillator dysfunction during and after magnetic resonance imaging. *Pacing Clin Electrophysiol* 2002; 25:1400-1402
57. Avery JE: Loss prevention case of the month. Not my responsibility! *J Tenn Med Assoc* 1988; 81:523-524
58. Bonnett CA, Elson JJ, Fogoros RN: Accidental deactivation of the automatic implantable cardioverter defibrillator. *Am Heart J* 1990; 120:696-697
59. Coman JA, Martin ET, Sandler DA, Thomas JR: Implantable cardiac defibrillator interactions with magnetic resonance imaging at 1.5 Tesla. *J Am Coll Cardiol* 2004; 43:138A
60. Erlebacher JA, Cahill PT, Pannizzo F, Knowles JR: Effect of magnetic resonance imaging on DDD pacemakers. *Am J Cardiol* 1986; 57:437-440
61. Fetter J, Aram G, Holmes DR Jr., Gray JE, Hayes DL: The effects of nuclear magnetic resonance imagers on external and implantable pulse generators. *Pacing Clin Electrophysiol* 1984; 7:720-727
62. Fiek M, Remp T, Reithmann C, Steinbeck G: Complete loss of ICD programmability after magnetic resonance imaging. *Pacing Clin Electrophysiol* 2000; 27:1002-1004
63. Fontain JM, Mohammed FB, Gottlieb C, Callans DJ, Marchlinski FE: Rapid ventricular pacing in a pacemaker patient undergoing magnetic resonance imaging. *Pacing Clin Electrophysiol* 1998; 21:1336-1339
64. Garcia-Bolao I, Albaladejo V, Benito A, Alegria E, Zubieta JL: Magnetic resonance imaging in a patient with a dual-chamber pacemaker. *Acta Cardiol* 1998; 53:33-35
65. Gimbel JR, Bailey SM, Tchou PJ, Ruggieri PM, Wilcox EL: Strategies for the safe magnetic resonance imaging of pacemaker-dependent patients. *Pacing Clin Electrophysiol* 2005; 28:1041-1046
66. Gimbel JR, Johnson D, Levine PA, Wilkoff BL: Safe performance of magnetic resonance imaging on five patients with permanent cardiac pacemakers. *Pacing Clin Electrophysiol* 1996; 19:913-919
67. Gimbel JR, Kanal E, Schwartz KM, Wilkoff BL: Outcome of magnetic resonance imaging (MRI) in selected patients with implantable cardioverter defibrillators (ICDs). *Pacing Clin Electrophysiol* 2005; 28:270-273
68. Gimbel JR, Trohman RL, Lindsay WC, Clair WK, Wilkoff BL: Strategies for the safe performance of magnetic resonance imaging in selected ICD patients. *Pacing Clin Electrophysiol* 2002; 25:618
69. Hayes DL, Holmes DR Jr., Gray JE: Effect of 1.5 Tesla nuclear magnetic resonance imaging scanner on implanted permanent pacemakers. *J Am Coll Cardiol* 1987; 10:782-786
70. Heatlie G, Pennell DJ: Cardiovascular magnetic resonance at 0.5T in five patients with permanent pacemakers. *J Cardiovasc Magn Reson* 2007; 9:15-19
71. Holmes DR Jr., Hayes DL, Gray JE, Merideth J: The effects of magnetic resonance imaging in implantable pulse generators. *Pacing Clin Electrophysiol* 1986; 9:360-370
72. Lauck G, von Smekal A, Wolke S, Seelos KC, Jung W, Manz M, Luderitz B: Effects of nuclear magnetic resonance imaging on cardiac pacemakers. *Pacing Clin Electrophysiol* 1995; 18:1549-1555
73. Luechinger R, Duru F, Scheidegger MB, Boesiger P, Dandinas R: Force and torque effects of a 1.5 Tesla MRI scanner on cardiac pacemakers and ICDs. *Pacing Clin Electrophysiol* 2001; 24:199-205

74. Luechinger R, Zeijlemaker VA, Pederson EM, Mortensen P, Falk E, Duru F, Candinas R, Boesiger P: In vivo heating of pacemaker leads during magnetic resonance imaging. *Eur Heart J* 2005; 26:376-383
75. Martin ET, Coman JA, Shellock FG, Pulling CC, Fair R, Jenkins K: Magnetic resonance imaging and cardiac pacemaker safety at 1.5 T. *J Am Coll Cardiol* 2004; 43:1315-1324
76. Pavlicek W, Geisinger M, Castle L, Borkowski GP, Meaney TF, Bream BL, Gallagher JH: The effects of nuclear magnetic resonance on patients with cardiac pacemakers. *Radiology* 1983; 147:149-153
77. Roguin A, Zviman MM, Meininger GR, Rodrigues ER, Dickfeld TM, Bluemke DA, Lardo A, Berger RD, Calkins H, Halperin HR: Modern pacemaker and implantable cardioverter/defibrillator systems can be magnetic resonance imaging safe: In vitro and in vivo assessment of safety and function at 1.5 T. *Circulation* 2004; 110:475-482
78. Rozner MA, Burton AW, Kumar AJ. Pacemaker complication during MRI: *J Am Coll Cardiol* 2005; 45:161-162
79. Schmiedel A, Hackenbroch M, Yang A, Nahle CP, Skowasch D, Meyer C, Schimpf R, Schild H, Sommer T: Magnetic resonance imaging of the brain in patients with cardiac pacemakers. In-vitro and in-vivo evaluation at 1.5 Tesla. *Rofo* 2005; 177:731-744
80. Shellock FG, Fieno DS, Thomson LJ, Talavage TM, Berman DS: Cardiac pacemaker: In vitro assessment at 1.5 T. *American Heart J* 2006; 2:436-443
81. Shellock FG, Fischer L, Fieno DS: Cardiac pacemakers and implantable cardioverter defibrillators: in vitro magnetic resonance imaging evaluation at 1.5-tesla. *J Cardiovasc Magn Reson* 2007; 9:21-31
82. Shellock FG, O'Neil M, Ivans V, Kelly D, O'Connor M, Toay L, Crues JV: Cardiac pacemakers and implantable cardioverter defibrillators are unaffected by operation of an extremity MR imaging system. *AJR Am J Roentgenol* 1999; 172:165-170
83. Sommer T, Vahiahaus C, Lauck G, von Smekal A, Reinke M, Hofer U, Block W, Traber F, Schneider C, Gieseke J, Jung W, Schild H: MR Imaging and cardiac pacemakers: in vitro evaluation and in vivo studies in 51 patients at 0.5 T. *Radiology* 2000; 215:869-879
84. Valhaus C, Sommer T, Lewalter T, Schimpf R, Schumacher B, Jung W, Luderitz B: Interference with cardiac pacemakers by magnetic resonance imaging: are there irreversible changes at 0.5 Tesla? *Pacing Clin Electrophysiol* 2001; 24:489-495
85. Gimbel JR, Lorig RJ, Wilkoff BL: Safe magnetic resonance imaging of pacemaker patients. *J Am Coll Cardiol* 1995; 25:11A
86. Crane BT, Gottschalk B, Kraut M, Aygun N, Niparko JK: Magnetic resonance imaging at 1.5 T after cochlear implantation. *Otol Neurotol* 2010; 31:1215-1220
87. Schueler BA, Parrish TB, Lin JC, Hammer BE, Pangrle BJ, Ritenour ER, Kucharczyk J, Truwit CL: MRI compatibility and visibility assessment of implantable medical devices. *J Magn Reson Imag* 1999;9:596-603
88. Shellock FG, Hatfield M, Simon BJ, Block S, Wamboldt R, Starewica PM, Punched WFB: Implantable spinal fusion stimulator: assessment of MRI safety. *J Magn Reson Imaging* 2000; 12:214-223
89. Bhidayasiri R, Bronstein JM, Sinha S, Krahl SE, Ahn S, Behnke EJ, Cohen MS, Frysinger R, Shellock FG: Bilateral neurostimulation systems used for deep brain stimulation: in vitro study of MRI-related heating at 1.5 T and implications for clinical imaging of the brain. *Magn Reson Imaging* 2005; 23:549-555
90. Carmichael DW, Pinto S, Limousin-Dowsey P, Thobois S, Allen PJ, Lemieux L, Yousry T, Thornton JS: Functional MRI with active, fully implanted, deep brain stimulation systems: safety and experimental confounds. *Neuroimage* 2007; 37:508-517

91. De Andres J, Valía JC, Cerda-Olmedo G, Quiroz C, Villanueva V, Martinez-Sanjuan V, de Leon-Casasola O: Magnetic resonance imaging in patients with spinal neurostimulation systems. *Anesthesiology* 2007; 106:779-786
92. Finelli DA, Rezai AR, Ruggieri PM, Tkach JA, Nyenhuis JA, Hrdlicka G, Sharan A, Gonzalez-Martinez J, Stypulkowski PH, Shellock FG: MR imaging-related heating of deep brain stimulation electrodes: in vitro study. *Am J Neuroradiol* 2002; 23:1795-802
93. Heller J, Brackman D, Tucci D, Nyenhuis J, Chou C: Evaluation of MRI compatibility of the modified nucleus multichannel auditory brainstem and cochlear implants. *Am J Otol* 1996; 17:724-729
94. Rezai AR, Finelli D, Nyenhuis JA, Hrdlicka G, Tkach J, Sharan A, Ruggieri P, Stypulkowski PH, Shellock FG: Neurostimulation systems for deep brain stimulation: in vitro evaluation of MRI-related heating at 1.5 tesla. *J Magn Reson Imaging* 2002; 15:241-250
95. Baker KB, Nyenhuis JA, Hrdlicka G, Rezai AR, Tkach JA, Shellock FG: Neurostimulation systems: assessment of magnetic field interactions associated with 1.5- and 3-Tesla MR systems. *J Magn Reson Imaging* 2005; 21:72-77
96. Utti RJ, Tsuboi Y, Pooley RA, Putzke JD, Turk, MF, Wszolek Z, Witte RJ, Wharen RE Jr.: Magnetic resonance imaging and deep brain stimulation. *Neurosurgery* 2002; 51:1423-1431
97. Williams MD, Antonelli PJ, Williams LS, Moorhead JE: Middle ear prosthesis displacement in high-strength magnetic fields. *Otol Neurotol* 2001; 22:158-161
98. Ferris NJ, Kavnoudias H, Thiel C, Stuckey S: The 2005 Australian MRI safety survey. *AJR Am J Roentgenol* 2007; 188:1388-1394
99. American Society of Anesthesiologists: Standards for Basic Anesthetic Monitoring. In: Standards, Guidelines and Statements: (last amended October 20, 2010, effective date July 1, 2011).<http://www.asahq.org/publicationsAndServices/standards/02.pdf>
100. Holshouser BA, Hinshaw DB, Shellock FG: Sedation, anesthesia, and physiologic monitoring during MR imaging: evaluation of procedures and equipment. *J Magn Reson Imaging* 1993; 3:553-558
101. Odegard KC, Dinardo JA, Tsai-Goddman B, Powell AJ, Geva T, Laussen PC: Anaesthesia considerations for cardiac MRI in infants and children. *Paediatr Anaesth* 2004; 14:471-476
102. Salvo I, Colombo S, Capocasa T, Torri G: Pulse oximetry in MRI units. *J Clin Anesth* 1990; 2:65-66
103. Barnett GH, Ropper AH, Johnson KA: Physiological support and monitoring of critically ill patients during magnetic resonance imaging. *J Neurosurg* 1988; 68:246-250
104. Henneberg S, Hok B, Wiklund L, Sjodin G: Remote auscultatory patient monitoring during magnetic resonance imaging. *J Clin Monit* 1992; 8:37-43
105. Mason KP, Burrows PE, Dorsey MM, Zurakowski D, Krauss B: Accuracy of capnography with a 30 foot nasal cannula for monitoring respiratory rate and end-tidal CO<sub>2</sub> in children. *J Clin Monit Comput* 2000; 16:259-262
106. Roth JLO, Nugent M, Gray JE, Julsrud RR: Patient monitoring during magnetic resonance imaging. *Anesthesiology* 1985; 62:80-83
107. Jorgensen NH, Messick JM, Gray J, Nugent M, Berquist TH: ASA monitoring standards and magnetic resonance imaging. *Anesth Analg* 1994;79:1141-1147
108. Beebe DS, Tran P, Bragg M, Stillman A, Truwitt C, Belani KG: Trained nurses can provide safe and effective sedation for MRI in pediatric patients. *Can J Anaesth* 2000; 47:205-210

109. Hubbard AM, Markowitz RI, Kimmel B, Kroger M, Bartko MB: Sedation for pediatric patients undergoing CT and MRI. *J Comput Assist Tomogr* 1992; 16:3-6
110. Li W, Wait SD, Ogg RJ, Scoggins MA, Zou P, Wheless J, Boop FA: Functional magnetic resonance imaging of the visual cortex performed in children under sedation to assist in presurgical planning. *J Neurosurg Pediatr* 2013; 11:543-546
111. Machata AM, Kabon B, Willschke H, Prayer D, Marhofer P: Upper airway size and configuration during propofol-based sedation for magnetic resonance imaging: an analysis of 138 infants and children. *Paediatr Anaesth* 2010; 20:994-1000
112. Manuli MA, Davies L: Rectal methohexital for sedation of children during imaging procedures. *AJR Am J Roentgenol* 1993; 160:577-580
113. Shepherd JK, Hall-Craggs MA, Finn JP, Bingham RM: Sedation in children scanned with high-field magnetic resonance; the experience at the Hospital for Sick Children, Great Ormond Street. *Br J Radiol* 1990; 63: 794-797
114. Slovis TL, Parks C, Reneau D, Becker CJ, Hersch J, Carver CD, Ross RD, Tech K, Towbin RB: Pediatric sedation: short-term effects. *Pediatr Radiol* 1993; 23:345-348
115. Volle E, Park W, Kaufman HJ: MRI examination and monitoring of pediatric patients under sedation. *Pediatr Radiol* 1996; 26:280-281
116. Greenberg SB, Faerber EN, Aspinall CL, Adams RC: High-dose chloral hydrate sedation for children undergoing MR imaging: safety and efficacy in relation to age. *AJR Am J Roentgenol* 1993; 161:639-641
117. Kannikeswaran N, Sethuraman U, Sivaswamy L, Chen X, Mahajan PV: Children with and without developmental disabilities: sedation medication requirements and adverse events related to sedation. *Pediatr Emerg Care* 2012; 28:1036-1040
118. Karian VE, Burrows PE, Zurakowski D, Connor L, Mason KP: Sedation for pediatric radiological procedures: analysis of potential causes of sedation failure and paradoxical reactions. *Pediatr Radiol* 1999; 29:869-873
119. Malviya S., Voepel-Lewis T., Eldevik O.P., Rockwell D.T., Wong J.H., Tait A.R: Sedation and general anaesthesia in children undergoing MRI and CT: adverse events and outcomes. *Br J Anaesth* 2000; 84:743-748
120. Fogel MA, Weinberg PM, Parave E, Harris C, Montenegro L, Harris MA, Concepcion M: Deep sedation for cardiac magnetic resonance imaging: a comparison with cardiac anesthesia. *J Pediatr* 2008; 152:534-259
121. Heng Vong C, Bajard A, Thiesse P, Bouffet E, Seban H, Marec Bérard P: Deep sedation in pediatric imaging: efficacy and safety of intravenous chlorpromazine. *Pediatr Radiol* 2012; 42:552-561
122. Jain R, Petrillo-Albarano T, Parks WJ, Linzer JF Sr, Stockwell JA: Efficacy and safety of deep sedation by non-anesthesiologists for cardiac MRI in children. *Pediatr Radiol* 2013; 43:605-611
123. Maruf AA, Hossain MD, Ahmed M, Samsad IA: Procedural sedation in children for magnetic resonance imaging - comparison between ketamine diazepam combination with midazolam fentanyl combination. *Mymensingh Med J* 2010; 19:60-65
124. Tith S, Lalwani K, Fu R: Complications of three deep sedation methods for magnetic resonance imaging. *J Anaesthesiol Clin Pharmacol* 2012; 28:178-184
125. Shorrab AA, Demain AD, Atallah MM: Multidrug intravenous anesthesia for children undergoing MRI: a comparison with general anesthesia. *Paediatr Anaesth* 2007; 17:1187-1193
126. Bloomfield EL, Masaryk TJ, Caplin A, Obuchowski NA, Schubert A, Hayden J, Ebrahim ZY, Ruggieri PM, Goske MJ, Ross JS: Intravenous sedation for MR imaging of

- the brain and spine in children: pentobarbital versus propofol. *Radiology* 1993; 186:93-97
127. Bluemke DA, Breiter SN: Sedation procedures in MR imaging: safety, effectiveness, and nursing effect on examinations. *Radiology* 2000; 216:645-652
  128. Bryan YF, Hoke LK, Taghon TA, Nick TG, Wang Y, Kennedy SM, Furststein JS, Kurth CD: A randomized trial comparing sevoflurane and propofol in children undergoing MRI scans. *Paediatr Anaesth* 2009; 19:672-681
  129. Cho JE, Kim WO, Chang DJ, Choi EM, Oh SY, Kil HK: Titrated propofol induction vs. continuous infusion in children undergoing magnetic resonance imaging. *Acta Anaesthesiol Scand* 2010; 54:453-457
  130. Connor L, Burrows PE, Zurakowski D, Bucci K, Gagnon DA, Mason KP: Effects of IV pentobarbital with and without fentanyl on end-tidal carbon dioxide levels during deep sedation. *AJR Am J Roentgenol* 2003; 181:1691-1694
  131. De Sanctis Briggs V: Magnetic resonance imaging under sedation in newborns and infants: a study of 640 cases using sevoflurane. *Paediatr Anaesth* 2005; 15:9-15
  132. Kaila R, Chen X, Kannikeswaran N: Postdischarge adverse events related to sedation for diagnostic imaging in children. *Pediatr Emerg Care* 2012; 28:796-801
  133. Machata AM, Willschke H, Kabon B, Kettner SC, Marhofer P: Propofol-based sedation regimen for infants and children undergoing ambulatory magnetic resonance imaging. *Br J Anaesth* 2008; 101:239-243
  134. Mason KP, Sanborn P, Zurakowski D, Karian VE, Connor L, Fontaine PJ, Burrows PE: Superiority of pentobarbital versus chloral hydrate for sedation in infants during imaging. *Radiology* 2004; 230:537-542
  135. Mason KP, Zurakowski D, Connor L, Karian VE, Fontaine PJ, Sanborn PA, Burrows PE: Infant sedation for MR imaging and CT: oral versus intravenous pentobarbital. *Radiology* 2004; 233:723-728
  136. Merola C, Albarracin C, Lebowitz P, Bienkowski RS, Barst SM: An audit of adverse events in children sedated with chloral hydrate or propofol during imaging studies. *Paediatr Anaesth* 1995; 5:375-378
  137. Oğurlu M, Orhan ME, Bilgin F, Sizlan A, Yanarateş O, Yilmaz N: Efficacy of different concentrations of sevoflurane administered through a face mask for magnetic resonance imaging in children. *Paediatr Anaesth* 2010; 20:1098-1104
  138. Pershad J, Wan J, Angheliescu DL: Comparison of propofol with pentobarbital/midazolam/fentanyl sedation for magnetic resonance imaging of the brain in children. *Pediatrics* 2007; 120:e629-e636
  139. Rangamani S, Varghese J, Li L, Harvey L, Hammel JM, Fletcher SE, Duncan KF, Danford DA, Kuttly S: Safety of cardiac magnetic resonance and contrast angiography for neonates and small infants: a 10-year single-institution experience. *Pediatr Radiol* 2012; 42:1339-1346
  140. Sanborn PA, Michna E, Zurakowski D, Burrows PE, Fontaine PJ, Connor L, Mason KP: Adverse cardiovascular and respiratory events during sedation of pediatric patients for imaging examinations. *Radiology* 2005; 237:288-294
  141. Vade A, Sukhani R, Dolenga M, Habisohn-Schuck C: Chloral hydrate sedation of children undergoing CT and MR imaging: safety as judged by American Academy of Pediatrics guidelines. *AJR Am J Roentgenol* 1995; 165:905-909
  142. Woodthorpe C, Trigg A, Alison G, Sury M: Nurse led sedation for paediatric MRI: progress and issues. *Paediatr Nurs* 2007; 19:14-18

PRACTICE ADVISORY

143. American Society of Anesthesiologists: Practice advisory for the prevention and management of operating room fires: An updated report. ANESTHESIOLOGY 2013; 118:271-290

DRAFT

*Appendix 1: Zone Definitions:*

**Zone I**

This region includes all areas that are freely accessible to the general public. This area is typically outside the MR environment itself and is the area through which patients, health care personnel, and other employees of the MR site access the MR environment.

**Zone II**

This area is the interface between the publicly accessible uncontrolled Zone I and the strictly controlled Zone III (see below). Typically, the patients are greeted in Zone II and are not free to move throughout Zone II at will, but rather are under the supervision of MR personnel. It is in Zone II that the answers to MR screening questions, patient histories, medical insurance questions, etc. are typically obtained.

**Zone III**

This area is the region in which free access by unscreened non-MR personnel or ferromagnetic objects or equipment can result in serious injury or death as a result of interactions between the individuals or equipment and the MR scanner's particular environment. These interactions include, but are not limited to, those with the MR scanner's static and time varying magnetic fields. All access to Zone III is to be strictly restricted, with access to regions within it (including Zone IV; see below) controlled by, and entirely under the supervision of, MR personnel.

**Zone IV**

This area is synonymous with the MR scanner magnet room itself. Zone IV, by definition, will always be located within Zone III as it is the MR magnet and its associated magnetic field, which generates the existence of Zone III.

*Appendix 2: Summary of Recommendations*

*I. Education*

- 619 • All anesthesiologists should have general safety education on the unique physical  
620 environment of the MRI scanner, and specific education regarding the specific features  
621 of individual scanners within their institution
- 622 ○ Education should emphasize safety for entering zones III and IV, with special  
623 emphasis on hazards in this environment and effects on monitoring capabilities
- 624 ○ Education should address potential health hazards (e.g., high decibel levels and high  
625 intensity magnetic fields)
- 626 ○ Education should address necessary precautions to deal with the specific field  
627 strength and the safety of the MRI scanners within their institutions
- 628 ○ Education should include information regarding ferromagnetic items (e.g.,  
629 stethoscopes, pens, wallets, watches, hair clips, name tags, pagers, cell phones, credit  
630 cards, batteries) and implantable devices (e.g., spinal cord stimulators, implanted  
631 objects) that should *not* be brought into zones III and IV of the MRI suite or should  
632 be brought in with caution
- 633 • Anesthesiologists should work in collaboration with radiologists, technologists, and  
634 physicists within their institutions to ensure that the above topics are included in their  
635 safety training programs
- 636 • Education should include how to safely respond to code blue situations in zones III and  
637 IV, and this information should be integrated into protocols for the designated code blue  
638 team.

*II. Screening of Anesthesia Care Providers and Ancillary Support Personnel*

- 639 • The anesthesiologist should work in collaboration with the MRI medical director or  
640 designee (e.g., safety officer) to ensure that all anesthesia team personnel entering zone  
641 III or IV have been screened for the presence of ferromagnetic materials, foreign bodies,  
642 or implanted devices.

*III. Patient Screening*

- 643 • For every case, the anesthesiologist should communicate with the patient, referring  
644 physician, and radiologist to determine whether the patient:
  - 645 ○ Presents with a high-risk medical condition (e.g., neonatal status or prematurity,  
646 intensive or critical care status, impaired respiratory function; hemodynamic  
647 instability and vasoactive infusion requirements, or comorbidities such as obesity  
648 and peripheral vascular disease)
  - 649 ○ Requires equipment (e.g., physiologic or invasive monitors; intubation, oxygenation  
650 or ventilation equipment)
  - 651 ○ Has been screened for implanted devices (e.g., pacemakers, cardioverter  
652 defibrillators, or nerve stimulators)
  - 653 ○ Has been screened for implanted ferromagnetic items (e.g., surgical clips, prosthetic  
654 heart valves)
  - 655 ○ Has been screened for the presence of *imbedded* foreign bodies (e.g., orbital iron  
656 filings, eyeliner tattoos)

- 657 • The anesthesiologist should communicate with the technologist to ensure that the patient  
658 has been screened for the presence of foreign bodies on the patient (*e.g.*, pierced jewelry,  
659 rings) prior to entering zone III
- 660 • If a patient presents with high-risk medical condition, the anesthesiologist should  
661 collaborate with all participants, including the referring physician, radiologist and  
662 technologist, to determine how the patient will be managed during the MRI procedure
- 663 ○ Anticipated changes in level of sedation, muscle relaxation, or ventilation may also  
664 place a patient in a high-risk situation
- 665 • For patients with acute or severe renal insufficiency, the anesthesiologist should not  
666 administer gadolinium because of the elevated risk of nephrogenic systemic fibrosis
- 667 • Anesthesiologists should work with their institutions to properly identify and label  
668 anesthesia-related equipment according to convention (safe, unsafe, or conditional) for  
669 each MRI scanner
- 670 • For each MRI location, anesthesiologists should determine the safety and effectiveness  
671 of the equipment needed by the patient during the procedure
- 672 ○ Care should be taken to assure that the patient's equipment does not interfere with  
673 image acquisition or quality
- 674 • Cardiac pacemakers and implantable cardioverter-defibrillators are generally  
675 contraindicated for MRI
- 676 ○ When MRI is considered essential by the referring physician and consulting  
677 radiologist, a plan for managing these patients during the scan should be developed  
678 in collaboration with the ordering physician, medical director or on-site radiologist  
679 and other appropriate consultants (*e.g.*, the patient's pacemaker specialist or  
680 cardiologist, the diagnostic radiologist, and the device manufacturer)
- 681 • MRI may be performed on a limited basis for patients with certain implanted electronic  
682 devices (*e.g.*, deep brain stimulators, vagal nerve stimulators, phrenic nerve stimulators,  
683 wire-containing thermolysis catheters, or cochlear implants)
- 684 ○ In consultation with the referring physician, the radiologist responsible for the  
685 procedure, and the neurosurgeon, the anesthesiologist should ensure that the  
686 presence of the device has been noted and determined to be MRI safe/conditional  
687 prior to imaging of these patients

#### IV. Preparation

- 688 • For every case, the anesthesiologist should prepare, with support personnel, a plan for  
689 providing optimal anesthetic care within the special environment of the MRI suite
- 690 ○ In addition to addressing the medical needs of the patient, features of the plan should  
691 include: (1) requirements of the scan and personnel needs, (2) positioning of  
692 equipment, (3) special requirements or unique issues of patient or imaging study, (4)  
693 positioning of the anesthesiologist and the patient, and (5) planning for emergencies.
- 694 • The anesthesiologist should communicate with the radiology personnel to determine the  
695 requirements for the scan (*e.g.*, duration of the scan, position of the patient or area of the  
696 body in the scanner, positioning of receiver coils, need for periods of paused respiration)
- 697 • The anesthesiologist should communicate with other anesthesia team members  
698 regarding individual roles for anesthetic care.
- 699 • The anesthesiologist should collaborate with the MR technologist and/or facility  
700 biomedical engineer to determine and demarcate the optimal and safe location of  
701 movable equipment in relation to the gauss lines within the MRI suite.

- 702 • The anesthesiologist should choose a location or position for optimal patient observation  
703 and vigilance during delivery of care, whether in Zone III or IV
- 704 ○ Anesthesiologists should have: (1) a clear line of sight of the patient and physiologic  
705 monitors, whether by direct observation or by video camera, (2) anesthetic delivery  
706 equipment located for optimal control of anesthetic depth and rapid intervention, and  
707 (3) access to hospital information systems integral to patient care
- 708 ○ In preparing for positioning, the anesthesiologist should take into account potential  
709 electromagnetic and auditory hazards.
- 710 • Anesthesiologists should prepare a plan for rapidly summoning additional personnel in  
711 the event of an emergency
- 712 ○ The anesthesiologist should ensure that (1) emergency equipment and drugs are  
713 immediately accessible, (2) emergency communication (*e.g.*, phone or code button)  
714 is immediately available, and (3) an evacuation plan is in place, including an  
715 appropriate location outside the scan room (zone IV) for resuscitation
- 716     ▪ This location should be complete with physiologic monitors, oxygen, suction,  
717 and other appropriate resuscitation equipment

V. *Patient management during MRI*

- 718 • **Monitoring**
- 719 ○ MRI patients should be monitored in a manner consistent with the ASA “Standards  
720 for basic anesthesia monitoring”
- 721 ○ The anesthesiologist should be familiar with the expected limitations of available  
722 monitoring equipment
- 723     ▪ Information from electrocardiograms may be limited due to superimposed  
724 voltages from blood flow in the high magnetic field (*e.g.*, ST segment  
725 interpretation may be unreliable, even with highly-filtered monitors).
- 726 ○ The anesthesiologist should make sure that all monitors used in zone IV are  
727 safe/conditional for the scan
- 728 ○ A monitor should be available to view vital signs from zone III when the anesthesia  
729 care provider is not in zone IV
- 730 ○ Additional care should be taken in positioning ECG and other monitor leads to  
731 eliminate burns, even with non-ferromagnetic leads
- 732 • **Anesthetic care**
- 733 ○ Although lighter levels of anesthesia may be appropriate during an MRI scan, the  
734 anesthesiologist should be aware that these lighter levels may result in airway  
735 complications (*e.g.*, laryngospasm, coughing or other airway compromise) which  
736 may necessitate interruption of the scan for urgent treatment and alteration of  
737 anesthetic depth
- 738     ▪ Institutional circumstances, patient characteristics, and anesthesiologist  
739 preference may warrant more aggressive airway management and deeper  
740 anesthetic levels
- 741 ○ Anesthesiologists should ensure that patients who receive moderate or deep sedation  
742 are monitored in a manner consistent with their institution’s protocol for monitoring  
743 similarly sedated patients elsewhere in the facility
- 744 ○ Monitoring of exhaled carbon dioxide should be considered for all patients receiving  
745 deep sedation and for patients whose ventilation cannot be directly observed during  
746 moderate sedation

- 747 ○ Monitoring oxygenation by pulse oximetry is not a substitute for monitoring
- 748 ventilatory function
- 749 ○ Equipment and drugs for anesthetic care in the MRI suite should mirror what is
- 750 available in other anesthetizing locations including: (1) an integrated anesthesia
- 751 machine, medical gases, and waste anesthesia gas disposal or gas scavenging, when
- 752 inhalational anesthesia is administered, (2) suction, (3) adequate electrical outlets
- 753 and lighting, and (4) storage areas for equipment and drugs
- 754 ○ Equipment used in the MRI suite should be appropriate for the age and size of the
- 755 patient
- 756 ○ MRI-safe/conditional anesthesia machines are always preferred for use in an MRI
- 757 facility
  - 758 ■ When an MRI-safe/conditional anesthesia machine is not available,
  - 759 inhalational anesthetics can be administered from an anesthesia machine
  - 760 inside zone III *via* an elongated circuit through a wave guide.
  - 761 ■ If total intravenous anesthesia (TIVA) is used, it should be administered by
  - 762 using: (1) MRI-safe/conditional pumps in zone IV, (2) traditional (*i.e.* MRI
  - 763 unsafe) pumps in zone III with intravenous tubing passed through a wave
  - 764 guide, or (3) periodic bolus injections in either zones III or IV
    - 765 ● Although an anesthesia machine may not be required for the
    - 766 administration of TIVA, there must be equipment immediately available
    - 767 for the administration of positive pressure ventilation with oxygen.
- 768 ● **Airway management**
  - 769 ○ The anesthesiologist should have an advance plan in place to deal with
  - 770 instrumentation of the airway and common airway problems (*e.g.*, obstruction,
  - 771 secretions, laryngospasm, apnea and hypoventilation) when patients are in an MRI
  - 772 environment
  - 773 ○ If the patient is at risk for airway compromise, more aggressive airway management
  - 774 (*e.g.*, use of a tracheal tube or LMA), should be instituted because the patient's
  - 775 airway may be less accessible when the patient is in the scanner
  - 776 ○ Complex airway management (*e.g.*, fiberoptic intubation) should be performed in a
  - 777 controlled environment outside of zone IV
  - 778 ○ Alternative airway devices should be immediately available in the MRI suite
  - 779 ○ Suction equipment should be immediately accessible to the patient's airway at all
  - 780 times

## VI. Management of Emergencies

- 781 ● When a patient has a medical emergency (*e.g.*, cardiopulmonary arrest) in the MRI
- 782 scanner, the following should occur: (1) immediately remove the patient from Zone IV
- 783 while initiating CPR, if indicated, (2) call for help, and (3) transport the patient to a
- 784 previously designated safe area for resuscitation that is not in zone IV
  - 785 ○ This location should be as close to zone IV as possible so as not to delay
  - 786 resuscitation efforts, and should contain the following resuscitation equipment: a
  - 787 defibrillator, vital signs monitors, and a code cart that includes resuscitation drugs,
  - 788 airway equipment, oxygen, and suction
- 789 ● When a fire occurs in the MRI suite, team members should perform their pre-assigned
- 790 fire management task as quickly as possible, in accordance with the ASA practice
- 791 advisory for the prevention and management of operating room fires

## PRACTICE ADVISORY

- 792 ○ If a team member cannot rapidly perform his or her task in the predetermined order,  
793 other team members should perform their tasks *without waiting*
- 794 ○ When a team member has completed a pre-assigned task, he or she should help other  
795 members perform tasks that are not yet complete
- 796 ● In the case of projectile emergencies, team members should perform their institution's  
797 protocol in reaction to this occurrence
- 798 ○ If possible, immediately remove the patient from zone IV and discontinue the scan
- 799 ○ If the patient is injured, proceed with medical emergency management as indicated  
800 above
- 801 ○ A controlled quench may be necessary in order to remove the patient from the bore
- 802 ● When a quench occurs, team members should perform their institution's protocol in  
803 reaction to this occurrence. If possible: (1) immediately remove the patient from zone  
804 IV and (2) immediately administer oxygen to the patient
- 805 ○ Powerful static magnetic fields may persist after a quench, and therefore the usual  
806 precautions apply when entering zone IV
- 807 ● Emergency response personnel should be restricted from entering zone IV during any  
808 environmental emergency because of the persistent magnetic field

### *VII. Post-procedure Care*

- 809 ● The anesthesiologist should collaborate with the radiologist and other staff in the post-  
810 procedure care of the patient
- 811 ● Patients receiving sedation or anesthesia within the MRI suite should have access to  
812 postanesthetic care consistent with that provided in other areas of the institution,  
813 including transport to other recovery rooms, dedicated intensive care, or recovery areas  
814 within the MRI suite
- 815 ● In all situations, intensive care and recovery areas should include access to vital sign  
816 monitors, oxygen, suction, resuscitation equipment, and trained personnel
- 817 ● Patients should be provided oral and written discharge instructions
- 818

819 *Appendix 3: Methods and Analyses:*

*A. State of the Literature.*

820 For this updated Advisory, a review of studies used in the development of original Advisory  
821 was combined with studies published subsequent to approval of the original Advisory in  
822 2008.<sup>††††</sup> The scientific assessment of this updated Advisory was based on evidence linkages or  
823 statements regarding potential relationships between patient care interventions and safety  
824 outcomes in the MRI suite. The evidence linkage *interventions* are listed below.<sup>§§§§</sup>

825 *Education:*

- 826 • MRI education for magnet hazards
- 827 • MRI education for monitoring limitations
- 828 • MRI education for long term health hazards

829 *Screening of anesthesia care providers and ancillary support personnel:*

- 830 • Mandatory screening of all personnel entering zone III or IV

831 *Patient screening:*

- 832 • Patient-related risks for adverse outcomes related to MRI
- 833 • Equipment-related risks for adverse outcomes related to MRI

834 *Preparation:*

- 835 • Planning for the anesthetic care of the patient for the scan
- 836 • Planning for rapidly summoning additional personnel in the event of an emergency

837 *Patient management during MRI:*

- 838 • Monitoring during MRI
- 839 • Anesthetic care during MRI
- 840 • Airway management during MRI

841 *Management of emergencies:*

- 842 • Medical emergencies
- 843 • Environmental emergencies

844 *Post-procedure care:*

- 845 • Post-procedure care consistent with that provided for other areas of the institution
- 846
- 847

848 For the literature review, potentially relevant studies were identified via electronic and  
849 manual searches of the literature. The updated searches covered a 7-year period from 2008

---

<sup>††††</sup> American Society of Anesthesiologists: Practice advisory on anesthetic care for magnetic resonance imaging. *ANESTHESIOLOGY* 2009;110:459-479

<sup>§§§§</sup> Unless otherwise specified, outcomes for the listed interventions refer to the occurrence of safety-based outcomes.

850 through 2014. Over 200 new citations that addressed topics related to the evidence linkages  
851 were identified. These articles were reviewed and those meeting the appropriate criteria as  
852 outlined in the “Focus” section above were combined with pre-2009 articles used in the original  
853 Advisory, resulting in a total of 183 articles that contained direct linkage-related evidence. A  
854 complete bibliography used to develop these Guidelines, organized by section, is available as  
855 Supplemental Digital Content 2, [http://links.lww.com/ALN/\\_\\_\\_](http://links.lww.com/ALN/___). No evidence linkage  
856 contained enough studies with well-defined experimental designs and statistical information to  
857 conduct a quantitative analysis (*i.e.*, meta-analysis).

858 For the original Advisory, interobserver agreement among Task Force members and two  
859 methodologists was established by interrater reliability testing. Agreement levels using a  $\kappa$   
860 statistic for two-rater agreement pairs were as follows: (1) type of study design,  $\kappa = 0.49$  to  
861  $0.85$ ; (2) type of analysis,  $\kappa = 0.54$  to  $0.93$ ; (3) evidence linkage assignment,  $\kappa = 0.77$  to  $1.00$ ;  
862 and (4) literature inclusion for database,  $\kappa = 0.78$  to  $1.00$ . Three-rater chance-corrected  
863 agreement values were: (1) study design,  $Sav = 0.65$ ,  $Var(Sav) = 0.009$ ; (2) type of analysis,  
864  $Sav = 0.69$ ,  $Var(Sav) = 0.010$ ; (3) linkage assignment,  $Sav = 0.85$ ,  $Var(Sav) = 0.004$ ; (4)  
865 literature database inclusion,  $Sav = 0.85$ ,  $Var(Sav) = 0.013$ . These values represent moderate to  
866 high levels of agreement.

867 *B. Consensus-Based Evidence.*

868 For the original Advisory, consensus was obtained from multiple sources, including: (1)  
869 survey opinion from consultants who were selected based on their knowledge or expertise in  
870 MRI, (2) survey opinions solicited from active members of the ASA, (3) testimony from  
871 attendees of a publicly-held open forum at two national anesthesia meetings, (4) Internet  
872 commentary, and (5) Task Force opinion and interpretation. The survey rate of return was  
873 63% ( $n = 50$  of 79) for the consultants, and 989 surveys were received from active ASA

PRACTICE ADVISORY

874 members. Results of the surveys are reported in tables 1 and 2, and in the text of the  
875 Advisory.

876 The consultants were asked to indicate which, if any, of the evidence linkages would change  
877 their clinical practices if the Advisory was instituted. The rate of return was 29% (n = 23 of  
878 79). The percent of responding consultants expecting a change in their practice associated with  
879 each linkage topic was as follows: (1) education, 30%, (2) screening of anesthesia care  
880 providers and ancillary support personnel, 13%, (3) patient screening, 26%, (4)  
881 preparation, 13%, (5) patient management during MRI: monitoring, 4%, (6) patient management  
882 during MRI: anesthetic care, 0%, (7) patient management during MRI: airway, 0%, (8) patient  
883 management during MRI : emergencies, 13%, and (9) post-procedure care, 9%. Seventy-four  
884 percent indicated that their clinical practice will not need new equipment, supplies or training in  
885 order to implement the Practice Advisory. Eighty-five percent indicated that the Advisory  
886 would not require ongoing changes in their practice which will affect costs. Ninety-five percent  
887 of the respondents indicated that the Advisory would have *no effect* on the amount of time spent  
888 on a typical case, and 5% indicated that there would be a ten minute increase in the amount  
889 spent on a typical case with the implementation of this Advisory.

**Table 1: Consultant Survey Responses** \*\*\*\*\*

	<u>N</u>	<u>Percent Responding to Each Item</u>				
		<u>Strongly Agree</u>	<u>Agree</u>	<u>Uncertain</u>	<u>Disagree</u>	<u>Strongly Disagree</u>
<b><i>Education:</i></b>						
1. All anesthesiologists should have general safety education on the unique physical environment of the MRI scanner	50	90.0*	10.1	0.0	0.0	0.0
2. All anesthesiologists should have specific education regarding the features of individual scanners within their institutions	50	58.0*	38.0*	2.0	2.0	0.0
3. All anesthesiologists should work in collaboration with radiologists, technologists, and physicists within their institutions to develop safety training programs	50	80.0*	16.0	2.0	2.0	0.0
<b><i>Screening of Anesthesia Care Providers and Ancillary Support Personnel:</i></b>						
4. The anesthesiologist should work in collaboration with the MRI medical director or designee to insure that all anesthesia team personnel entering zone III or IV have been properly screened	50	60.0*	34.0	4.0	2.0	0.0
<b><i>Patient Screening:</i></b>						
5a. For every case, the anesthesiologist should communicate with the patient and radiologist or referring physician to determine whether the patient has a high-risk medical condition	50	58.0*	20.0	10.0	10.0	2.0
5b. If the patient presents with high-risk medical condition, the anesthesiologist should collaborate with all participants, including the referring physician, radiologist and technologist, to determine how the patient will be managed during the MRI procedure	50	58.0*	26.0	4.0	10.0	2.0
5c. For patients with acute or severe renal insufficiency, the anesthesiologist should not administer gadolinium because of the elevated risk of nephrogenic systemic fibrosis	49	34.7	34.7*	26.5	4.1	0.0
6a. For every case, the anesthesiologist should communicate with the radiologist or referring physician to determine whether the patient requires equipment that may pose a risk during the scan	49	28.6	36.7*	18.4	14.3	2.0

\*\*\*\*\* N = the number of consultants who responded to each item. An asterisk beside a percentage score indicates the median.

PRACTICE ADVISORY

6b. Anesthesiologist should determine the safety and effectiveness of the equipment needed by the patient during the procedure for each MRI location	50	46.0	34.0*	10.0	10.0	0.0
6c. Anesthesiologists should work with their institutions to properly identify and label anesthesia-related equipment according to convention (safe, unsafe, or conditional) for each MRI scanner	50	74.0*	26.0	0.0	0.0	0.0
6d. Care should be taken to assure that anesthesia equipment does not interfere with image acquisition or quality	50	68.0*	30.0	2.0	0.0	0.0
7a. In general, MRI should not be performed on patients with implanted electronic devices	50	22.0	48.0*	14.0	14.0	2.0
7b. When MRI is considered essential by the referring physician and consulting radiologist, a plan for managing patient with implanted electronic devices during the scan should be developed in collaboration with the referring physician, medical director, or on-site radiologist and other appropriate consultants	50	72.0*	26.0	0.0	2.0	0.0
<b>Preparation:</b>						
8. For every case, the anesthesiologist should prepare, with support personnel, a plan for providing optimal anesthetic care within the special environment of the MRI suite	50	72.0*	26.0	0.0	2.0	0.0
9. The anesthesiologist should communicate with the radiology personnel to determine the requirements for the scan (e.g., duration of the scan, position of the patient or area of the body in the scanner, positioning of receiver coils, need for periods of paused respiration)	50	68.0*	30.0	0.0	2.0	0.0
10. The anesthesiologist should collaborate with the MRI technologist and/or facility biomedical engineer to determine and demarcate the optimal and safe location of movable equipment in relation to the gauss lines within the MRI suite	50	62.0*	34.0	2.0	0.0	2.0
11. Because line of sight within the bore will vary depending on the facility, the anesthesiologist should choose a location or position for optimal patient observation and vigilance during delivery of care, whether in Zone III or IV	50	64.0*	28.0	8.0	0.0	0.0

PRACTICE ADVISORY

12. The anesthesiologist should prepare a plan for rapidly summoning additional personnel in the event of an emergency	50	82.0*	18.0	0.0	0.0	0.0
--	----	-------	------	-----	-----	-----

**Patient management during MRI:**

**Monitoring**

13. MRI patients should be monitored in a manner consistent with the ASA “Standards for Basic Anesthesia Monitoring”	50	72.0*	26.0	2.0	0.0	0.0
14. Anesthesiologists should be familiar with the expected limitations of available monitoring equipment	50	84.0*	16.0	0.0	0.0	0.0
15. The anesthesiologist should make sure that all monitors used in Zone IV are safe/conditional for the scan	50	82.0*	12.0	0.0	4.0	2.0
16. A monitor should be available to view vital signs from Zone IV when the anesthesia care provider is not in zone IV	50	78.0*	16.0	6.0	0.0	0.0

**Anesthetic care**

17. In general, because MRI is a non-painful procedure, lighter levels of anesthesia may be appropriate, recognizing that institutional circumstances, patient preference, and anesthesiologist preference may warrant more aggressive airway management and deeper anesthetic levels	50	58.0*	34.0	2.0	6.0	0.0
18. Anesthesiologists should ensure that patients who receive moderate or deep sedation are monitored in a manner consistent with their institution’s protocol for monitoring similarly sedated patients elsewhere in the facility	50	82.0*	18.0	0.0	0.0	0.0
19. Equipment and drugs for anesthetic care in the MRI suite should mirror what is available in the OR	50	76.0*	18.0	4.0	2.0	0.0
20a. When a MRI-safe/conditional anesthesia machine is not available, inhalation anesthetics may be administered from an anesthesia machine inside zone III <i>via</i> an elongated circuit through a wave guide	50	6.0	30.0	24.0*	34.0	6.0
20b. If total intravenous anesthesia is used, it should be administered by using: (1) MRI-safe/conditional pumps in zone IV, (2) traditional ( <i>i.e.</i> , MRI-unsafe) pumps in zone III with the intravenous tubing						

PRACTICE ADVISORY

passed through a wave guide, or (3) periodic bolus injections in either zones III or IV 50 30.0 58.0\* 10.0 2.0 0.0

**Airway management**

- 21. The anesthesiologist should have an advance plan in place to deal with instrumentation of the airway and common airway problems when patients are in a MRI environment 50 88.0\* 12.0 0.0 0.0 0.0
- 22. If the patient is at risk for airway compromise, more aggressive airway management (e.g., use of a tracheal tube or LMA) should be instituted because the patient’s airway may be less accessible when the patient is in the scanner 50 58.0\* 34.0 6.0 2.0 0.0
- 23. Complex airway management (e.g., fiberoptic intubation) should be performed in a controlled environment outside of zone IV 50 76.6\* 18.0 6.0 0.0 0.0
- 24. Alternative airway devices should be immediately available in the MRI suite 50 78.0\* 16.0 4.0 2.0 0.0
- 25. Suction equipment should be immediately accessible to the patient’s airway at all times 49 91.8\* 6.1 0.0 2.1 0.0

**Management of emergencies**

- 26a. When a patient has a medical emergency (e.g., cardiopulmonary arrest) in the MRI scanner, the following should occur: (1) initiate CPR, when needed, while immediately removing the patient from zone IV, (2) call for help, and (3) transport the patient to a previously designated safe a location in proximity to the MRI suite 49 81.6\* 18.4 0.0 0.0 0.0
- 26b. The designated safe location should contain the following resuscitation equipment: a defibrillator, vital signs monitors, and a code cart that includes resuscitation drugs, airway equipment, oxygen, and suction 49 85.7\* 14.3 0.0 0.0 0.0
- 27. When a fire occurs in the MRI suite, team members should perform their pre-assigned fire management task as quickly as possible, in accordance with the ASA “Practice Advisory for the Prevention and Management of Operating Room Fires” 49 71.4\* 14.3 14.3 0.0 0.0
- 28a. When a quench occurs, team members should perform their institution’s protocol in reaction to this occurrence 49 65.3\* 28.6 6.1 0.0 0.0
- 28b. When a quench occurs, if possible: (1) immediately remove the patient from

PRACTICE ADVISORY

zone IV and (2) immediately administer oxygen to the patient

49 55.1\* 22.5 20.4 2.0 0.0

29. Since powerful static magnetic fields may persist after a quench or fire, emergency response personnel should be restricted from entering zone IV

49 44.9 26.5\* 20.4 8.2 0.0

***Post-procedure care:***

30. The anesthesiologist should collaborate with the radiologist and other staff in the postanesthetic care of the patient

50 62.0\* 28.0 0.0 10.0 0.0

31. Patients receiving sedation or anesthesia within the MRI suite should have access to postanesthetic care consistent with that provided in other areas of the institution


50 82.0\* 16.0 0.0 2.0 0.0

32. In all situations, intensive care and recovery areas should include access to vital sign monitors, oxygen, suction, and trained personnel

50 84.0\* 14.0 2.0 0.0 0.0

33. Patients should be provided written discharge instructions

50 66.6\* 32.0 2.0 0.0 0.0



**Table 2: ASA Membership Survey Responses<sup>†††††</sup>**

	N	<u>Percent Responding to Each Item</u>				
		<u>Strongly Agree</u>	<u>Agree</u>	<u>Uncertain</u>	<u>Disagree</u>	<u>Strongly Disagree</u>
<b><i>Education:</i></b>						
1. All anesthesiologists should have general safety education on the unique physical environment of the MRI scanner	989	73.6*	25.0	1.0	0.2	0.2
2. All anesthesiologists should have specific education regarding the features of individual scanners within their institutions	986	33.7	42.4*	18.4	5.1	0.5
3. All anesthesiologists should work in collaboration with radiologists, technologists and physicists within their institutions to develop safety training programs	989	47.0	41.3*	8.1	3.4	0.2
<b><i>Screening of Anesthesia Care Providers and Ancillary Support Personnel:</i></b>						
4. The anesthesiologist should work in collaboration with the MRI medical director or designee to insure that all anesthesia team personnel entering zone III or IV have been properly screened	988	43.5	45.5*	8.0	2.8	0.2
<b><i>Patient Screening:</i></b>						
5a. For every case, the anesthesiologist should communicate with the patient and radiologist or referring physician to determine whether the patient has a high-risk medical condition	988	54.7*	30.6	6.7	6.9	1.2
5b. If the patient presents with high-risk medical condition, the anesthesiologist should collaborate with all participants, including the referring physician, radiologist and technologist, to determine how the patient will be managed during the MRI procedure	983	53.8*	34.2	4.6	6.4	1.0
5c. For patients with acute or severe renal insufficiency, the anesthesiologist should not administer gadolinium because of the elevated risk of nephrogenic systemic fibrosis	981	23.7	29.5*	42.9	3.7	0.3
6a. For every case, the anesthesiologist should communicate with the radiologist or referring physician to determine whether the patient requires equipment that may pose						

<sup>†††††</sup> N = the number of ASA members who responded to each item. An asterisk beside a percentage score indicates the median.

PRACTICE ADVISORY

a risk during the scan	976	36.2	38.1*	10.5	12.9	2.4
6b. Anesthesiologist should determine the safety and effectiveness of the equipment needed by the patient during the procedure for each MRI location	977	46.9	38.4*	6.7	6.4	1.7
6c. Anesthesiologists should work with their institutions to properly identify and label anesthesia-related equipment according to convention (safe, unsafe, or conditional) for each MRI scanner	981	56.6*	38.8	3.0	1.5	0.1
6d. Care should be taken to assure that anesthesia equipment does not interfere with image acquisition or quality	980	46.2	49.4	3.1	1.0	0.3
7a. In general, MRI should not be performed on patients with implanted electronic devices	982	27.8	42.9*	22.2	6.7	0.4
7b. When MRI is considered essential by the referring physician and consulting radiologist, a plan for managing patient with implanted electronic devices during the scan should be developed in collaboration with the referring physician, medical director, or on-site radiologist and other appropriate consultants	979	53.7*	41.6	2.8	1.3	0.6
<b>Preparation:</b>						
8. For every case, the anesthesiologist should prepare, with support personnel, a plan for providing optimal anesthetic care within the special environment of the MRI suite	977	63.2*	33.6	1.7	1.1	0.4
9. The anesthesiologist should communicate with the radiology personnel to determine the requirements for the scan ( <i>e.g.</i> , duration of the scan, position of the patient or area of the body in the scanner, positioning of receiver coils, need for periods of paused respiration)	980	64.5*	33.1	1.2	1.2	0.0
10. The anesthesiologist should collaborate with the MRI technologist and/or facility biomedical engineer to determine and demarcate the optimal and safe location of movable equipment in relation to the gauss lines within the MRI suite	974	48.8	43.2*	6.7	1.2	0.1
11. Because line of sight within the bore will vary depending on the facility, the anesthesiologist should choose a location or position for optimal patient observation and vigilance during delivery of care, whether in Zone III or IV	982	53.8*	39.3	5.1	1.3	0.5

PRACTICE ADVISORY

12. The anesthesiologist should prepare a plan for rapidly summoning additional personnel in the event of an emergency	978	70.6*	28.0	1.0	0.4	0.0
--	-----	-------	------	-----	-----	-----

**Patient management during an MRI:**

**Monitoring**

13. MRI patients should be monitored in a manner consistent with the ASA “Standards for Basic Anesthesia Monitoring”	977	73.7*	22.5	1.4	1.8	0.5
14. Anesthesiologists should be familiar with the expected limitations of available monitoring equipment	978	71.9*	27.8	0.2	0.0	0.1
15. The anesthesiologist should make sure that all monitors used in Zone IV are safe/conditional for the scan	977	68.3*	27.7	2.4	1.3	0.3
16. A monitor should be available to view vital signs from Zone IV when the anesthesia care provider is not in zone IV	976	71.6*	24.7	3.5	0.1	0.1

**Anesthetic care**

17. In general, because MRI is a non-painful procedure, lighter levels of anesthesia may be appropriate, recognizing that institutional circumstances, patient preference, and anesthesiologist preference may warrant more aggressive airway management and deeper anesthetic levels	976	53.3*	43.3	1.6	1.2	0.5
18. Anesthesiologists should ensure that patients who receive moderate or deep sedation are monitored in a manner consistent with their institution’s protocol for monitoring similarly sedated patients elsewhere in the facility	976	66.9*	30.2	1.3	1.1	0.4
19. Equipment and drugs for anesthetic care in the MRI suite should mirror what is available in the OR	980	61.4*	33.3	3.3	2.0	0.0
20a. When a MRI-safe/conditional anesthesia machine is not available, inhalation anesthetics may be administered from an anesthesia machine inside zone III <i>via</i> an elongated circuit through a wave guide	975	10.3	22.8	31.0*	29.1	6.9
20b. If total intravenous anesthesia is used, it should be administered by using: (1) MRI-safe/conditional pumps in zone IV, (2) traditional ( <i>i.e.</i> , MRI-unsafe) pumps in zone III with the intravenous tubing passed through a wave guide, or (3) periodic						

PRACTICE ADVISORY

bolus injections in either zones III or IV 978 24.0 53.2\* 12.0 8.7 2.2

**Airway management**

- 21. The anesthesiologist should have an advance plan in place to deal with instrumentation of the airway and common airway problems when patients are in a MRI environment 979 79.6\* 20.1 0.3 0.0 0.0
- 22. If the patient is at risk for airway compromise, more aggressive airway management (*e.g.*, use of a tracheal tube or LMA) should be instituted because the patient’s airway may be less accessible when the patient is in the scanner 981 72.8\* 23.0 2.6 1.6 0.0
- 23. Complex airway management (*e.g.*, fiberoptic intubation) should be performed in a controlled environment outside of zone IV 981 71.9\* 24.5 2.7 1.0 0.0
- 24. Alternative airway devices should be immediately available in the MRI suite 981 70.2\* 26.1 2.5 1.2 0.0
- 25. Suction equipment should be immediately accessible to the patient’s airway at all times 978 86.4\* 12.8 0.7 0.1 0.0

**Management of emergencies**

- 26a. When a patient has a medical emergency (*e.g.*, cardiopulmonary arrest) in the MRI scanner, the following should occur: (1) initiate CPR, when needed, while immediately removing the patient from zone IV, (2) call for help, and (3) transport the patient to a previously designated safe a location in proximity to the MRI suite 976 72.2\* 25.7 1.8 0.2 0.0
- 26b. The designated safe location should contain the following resuscitation equipment: a defibrillator, vital signs monitors, and a code cart that includes resuscitation drugs, airway equipment, oxygen, and suction 978 79.4\* 19.9 0.5 0.1 0.1
- 27. When a fire occurs in the MRI suite, team members should perform their pre-assigned fire management task as quickly as possible, in accordance with the ASA “Practice Advisory for the Prevention and Management of Operating Room Fires” 970 65.4\* 30.4 4.5 0.0 0.1
- 28a. When a quench occurs, team members should perform their institution’s protocol in reaction to this occurrence 967 49.1 29.7\* 21.2 0.0 0.0
- 28b. When a quench occurs, if possible: (1) immediately remove the patient from zone IV and (2) immediately administer oxygen to the patient 963 49.0 27.6\* 22.5 0.7 0.1

PRACTICE ADVISORY

29. Since powerful static magnetic fields may persist after a quench or fire, emergency response personnel should be restricted from entering zone IV

973	22.3	28.7*	41.0	7.2	0.8
-----	------	-------	------	-----	-----

**Post-procedure care:**

30. The anesthesiologist should collaborate with the radiologist and other staff in the postanesthetic care of the patient

979	41.5	41.5*	4.9	10.5	1.6
-----	------	-------	-----	------	-----

31. Patients receiving sedation or anesthesia within the MRI suite should have access to postanesthetic care consistent with that provided in other areas of the institution

981	72.0*	27.1	0.5	0.4	0.0
-----	-------	------	-----	-----	-----

32. In all situations, intensive care and recovery areas should include access to vital sign monitors, oxygen, suction, and trained personnel

977	77.7*	22.3	0.0	0.0	0.0
-----	-------	------	-----	-----	-----

33. Patients should be provided written discharge instructions

981	53.1*	39.4	5.9	1.5	0.1
-----	-------	------	-----	-----	-----

DRAFT